EGFR exon 19 deletion / L858R

Approved therapies

Approvals in the United States (FDA) and the European Union (EMA), one row per drug, regimen and tumour type. Where we have them, the pivotal trial's results and side effects are shown under each therapy, from the official label. Results from different trials are not directly comparable: patients, earlier treatments and comparators differ.

Companion diagnostic tests

Tests the FDA has approved to select patients for a specific therapy. Other validated tests are often used in practice, especially in Europe.

Drugs in active trials

Targeted drugs, antibody-drug conjugates and immunotherapies in active trials on this page, approved ones first, then by the furthest phase reached. Chemotherapy and supportive medicines are left out. "Not yet classified" means an early drug known only by its code.

25 of 151 drugs shown

Show all 151 drugs

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months: the date the main results are due to be collected, according to the sponsor. Results are usually published months later, and these dates often slip.

Show all 75 readouts

Companies

Industry sponsors leading active trials, by number of trials. Each square is one trial, shaded by phase.

1. AstraZeneca 21
2. Johnson & Johnson 10
3. Hansoh Pharma 8
4. Avistone Biotechnology 7
5. Betta Pharmaceuticals 6
6. Baili-Bio / SystImmune 5
7. CSPC 5
8. Kelun-Biotech 5
9. Dizal Pharmaceuticals 5
10. Daiichi Sankyo 4
11. AbbVie 4
12. Allist Pharmaceuticals 3
13. Bristol Myers Squibb 3
14. Jiangsu Aosaikang Pharmaceutical 3
15. Jiangsu Hengrui 3

Phase 1 Phase 2 Phase 3 Phase 4 No phase

Trials

Matched automatically from registry text, so a few trials may only mention EGFR exon 19 deletion / L858R rather than require it. Check the quoted criterion, and the registry entry before relying on a match.

399 of 1,034 trials shown

1. A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

   Not yet recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai Started 2026Primary completion 2029-08 NCT07469488

   Enhanced dermatologic managementEnhanced IRR ProphylaxisEnhanced VTE Prophylaxis (Cohort 1 only)

   EGFR mutation must be an Ex19del or Ex21 L858R substitution.

   NSCLC (Advanced Non-small Cell Lung Cancer), VTE (Venous Thromboembolism), Rash Due to Epidermal Growth Factor Receptor Inhibitors, Infusion Reaction

2. Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

   Recruiting Phase 4 AstraZeneca Started 2026Primary completion 2030-05 NCT07279935

   osimertinib FDA EUcisplatincarboplatinpemetrexed

   EGFR mutation (Exon 19del/Exon 21 L858R)-reconfirmed for study entry (mandatory undergo NGS by plasma, and tissue i…

   Non-small Cell Lung Cancer

3. Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

   Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Started 2025Primary completion 2027-05 NCT07092202

   furmonertinibpemetrexed

   …ed by histological or cytological specimens tested in the central laboratory to have EGFR exon 19 deletion mutation (19DEL) or exon 21 L858R point mutation (L858R), which can exist alone or in com…

   Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor

4. Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

   Recruiting Phase 3 National Taiwan University Hospital Started 2026Primary completion 2031-08 NCT07738172

   osimertinib FDA EU

   EGFR sensitizing mutation limited to exon 19 deletion or exon 21 L858R.

   Lung Neoplasms, Non-Small Cell Lung Cancer

5. Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

   Recruiting Phase 3 MediLink Therapeutics Started 2026Primary completion 2028-08 NCT07416994

   YL202docetaxel

   …vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

   Non-Small Cell Lung Cancer

6. A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

   Not yet recruiting Phase 3 CSPC Started 2026Primary completion 2026-12 NCT07376382

   SYS6010osimertinib FDA EUpemetrexed

   Carry at least one EGFR-sensitive mutation (ex19del or L858R, which can be combined with other EGFR mutations).

   NSCLC

7. ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

   Not yet recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2026Primary completion 2030-12 NCT07897188

   ASKC202ASKC202 placeboosimertinib FDA EUpemetrexedcisplatincarboplatinlimertinib

   The tumor harbors EGFR sensitizing mutation (Ex19Del or L858R).

   EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive

8. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

   Recruiting Phase 3 Bristol Myers Squibb Started 2026Primary completion 2031-12 NCT07680790

   izalontamab brengitecanosimertinib FDA EUpemetrexedcarboplatincisplatin

   Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)

   Non-Small Cell Lung Cancer

9. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

   Recruiting Phase 2/3 AbbVie Started 2025Primary completion 2036-11 NCT07005102

   telisotuzumab adizutecanosimertinib FDA EUcisplatincarboplatinpemetrexed

   …d metastatic/locally advanced non-squamous NSCLC with documented classical EGFR mutation (Exon 19 Del or Exon 21 L858R) either alone or in combination with other EGFR mutations as detected by…

   Non-Squamous Non-Small Cell Lung Cancer, c-MET

10. A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting Phase 2/3 AbbVie Started 2025Primary completion 2030-09 NCT07155187

    telisotuzumab adizutecanosimertinib FDA EU

    …vanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R mutation.

    Non-Small Cell Lung Cancer, c-MET

11. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    Recruiting Phase 2/3 Bristol Myers Squibb Started 2025Primary completion 2028-12 NCT07100080

    izalontamab brengitecancarboplatincisplatinpemetrexed

    Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).

    Non-Small Cell Lung Cancer

12. A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

    Recruiting Phase 3 Allist Pharmaceuticals Started 2024Primary completion 2029-03 NCT06970639

    furmonertinibcarboplatincisplatinpemetrexedosimertinib FDA EU

    Confirmed EGFR sensitizing mutations (ex19del or L858R) via tumor tissue/cytology/blood testing;

    NSCLC Patients With Brain Metastasis

13. Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

    Not yet recruiting Phase 3 Fudan University Started 2024Primary completion 2026-03 NCT06323148

    osimertinib FDA EUNo adjuvant therapy

    …lar testing (such as ARMS-PCR or high-throughput sequencing), specifically with mutations 19del or 21L858R.

    Status may be outdated, last updated 2024-03-21Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease

14. Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

    Recruiting Phase 3 Peking Union Medical College Hospital Started 2024Primary completion 2026-12 NCT06674343

    furmonertinib

    …ents have been confirmed by local laboratory to have one of the following EGFR mutations: 19Del or L858R (single or compound)

    Advanced or Metastatic Non-small Cell Lung Cancer

15. A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Active, not recruiting Phase 3 AstraZeneca Started 2024Primary completion 2027-01 NCT06417814

    datopotamab deruxtecan FDAosimertinib FDA EUpemetrexedcarboplatincisplatin

    …pidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKis\] sensitivity \[Ex19del, L858R, G719X, S768I, or L861Q\], either alone or in combination with other EGFR mutation…

    Metastatic Non-small Cell Lung Cancer

16. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

    Recruiting Phase 3 AstraZeneca Started 2024Primary completion 2028-03 NCT06350097

    osimertinib FDA EUdatopotamab deruxtecan FDA

    … least 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del or L858R), either alone or in combination with other genomic alterations, which may inclu…

    Non-small Cell Lung Cancer

17. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

    Not yet recruiting Phase 3 Suzhou Puhe Pharmaceutical Technology Started 2023Primary completion 2025-07 NCT05767892

    YK-209A tabletpemetrexedcarboplatincisplatin

    …mutations for which there are approved anti-EGFR tyrosine kinase inhibitors \[TKIs\] (ie, exon 19 del, L858R, T790M, L861Q, G719X, or S768I, where X is any other amino acid).

    Status may be outdated, last updated 2023-04-05Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

18. Phase III Study of AK112 for NSCLC Patients

    Active, not recruiting Phase 3 Summit Therapeutics Started 2023Primary completion 2025-04 NCT06396065

    ivonescimabpemetrexedcarboplatin

    …tumor histology or cytology or blood test before enrollment (eg, exon 18 point mutations, exon 19 deletions, exon 20 point mutations, and exon 21 point mutations).

    Non-Squamous Non-small Cell Lung Cancer

19. Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

    Recruiting Phase 3 Shanghai Cancer Hospital Started 2023Primary completion 2027-12 NCT05800223

    aumolertinib

    5. epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation (alone or in combination with other EGFR mutatio…

    Status may be outdated, last updated 2023-04-05Non-small Cell Lung Cancer Metastatic

20. Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

    Recruiting Phase 3 Sun Yat-sen University Started 2023Primary completion 2028-12 NCT05768490

    aumolertinib

    EGFR sensitivity mutation (exon19del or exon21 L858R);

    Status may be outdated, last updated 2023-03-14Brain Metastases, Radiotherapy, EGFR Activating Mutation

21. SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

    Recruiting Phase 3 Nanjing Sanhome Pharmaceutical Started 2023Primary completion 2028-02 NCT06080776

    SH-1028 tablets

    Patients must harbor one of the two common sensitizing EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M, the mu…

    Status may be outdated, last updated 2023-10-12Non-small Cell Lung Cancer

22. Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

    Recruiting Phase 3 Betta Pharmaceuticals Started 2023Primary completion 2028-04 NCT06041776

    befotertinibicotinib

    …bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

    Status may be outdated, last updated 2023-09-22Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy

23. A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

    Active, not recruiting Phase 3 AstraZeneca Started 2022Primary completion 2027-08 NCT05120349

    osimertinib FDA EU

    A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.

    Non-Small Cell Lung Cancer

24. MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

    Active, not recruiting Phase 3 Guangdong Association of Clinical Trials Started 2022Primary completion 2026-12 NCT04841811

    aumolertinib

    …es effusions, and pericardial effusions are confirmed to be EGFR sensitive mutations (ie, exon 19 deletion or L858R, alone or coexisting, Or with other EGFR mutations, but patients with EGFR20 exo…

    Lung Cancer

25. HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

    Active, not recruiting Phase 3 Daiichi Sankyo Started 2022Primary completion 2024-05 NCT05338970

    patritumab deruxtecanPlatinum-based chemotherapy

    … documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R at diagnosis or thereafter.

    Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

26. Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

    Active, not recruiting Phase 3 AstraZeneca Started 2022Primary completion 2026-07 NCT05261399

    savolitinibosimertinib FDA EUpemetrexedcisplatincarboplatin

    Must have at least one documented sensitising EGFR mutation: exon19 deletion, L858R mutation, and/or T790M.

    Carcinoma, Non-Small-Cell Lung

27. A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

    Active, not recruiting Phase 3 Johnson & Johnson Started 2022Primary completion 2024-01 NCT05388669

    lazertinib FDA EUamivantamab FDA EU

    …cell lung cancer (NSCLC), characterized by either epidermal growth factor receptor (EGFR) Exon 19 deletion (Exon 19del) or Exon 21 leucine 858 to arginine substitution (Exon 21 L858R) mutation by …

    Advanced or Metastatic Non-small Cell Lung Cancer

28. A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

    Active, not recruiting Phase 3 AstraZeneca Started 2021Primary completion 2024-10 NCT04765059

    osimertinib FDA EUpemetrexedcisplatincarboplatin

    …) mutations known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations, which may include T7…

    Non-small Cell Lung Cancer

29. A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

    Active, not recruiting Phase 3 Johnson & Johnson Started 2021Primary completion 2023-07 NCT04988295

    lazertinib FDA EUamivantamab FDA EUpemetrexedcarboplatin

    …dvanced or metastatic disease diagnosis by either epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R mutation

    Carcinoma, Non-Small-Cell Lung

30. Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

    Active, not recruiting Phase 3 Hansoh Pharma Started 2021Primary completion 2024-06 NCT04923906

    aumolertinib

    …arbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations assessed by central tes…

    Non-small Cell Lung Cancer

31. To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

    Recruiting Phase 3 Allist Pharmaceuticals Started 2021Primary completion 2026-12 NCT04853342

    furmonertinib

    …bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

    Non-small Cell Lung Carcinoma

32. Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

    Active, not recruiting Phase 3 Li Zhang, MD Started 2021Primary completion 2025-11 NCT04695925

    osimertinib FDA EUpemetrexedcarboplatin

    …V or recurrent non-squamous non-small cell lung carcinoma with activating EGFR mutations (exon 19 deletion or exon 21 L858R point mutation) and concurrent TP53 mutations;

    Non-small Cell Carcinoma, EGFR Gene Mutation

33. Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

    Active, not recruiting Phase 3 HUTCHMED Started 2021Primary completion 2028-05 NCT05009836

    savolitinibosimertinib FDA EU

    …arrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI (i.e., exon 19 deletion, and L858R) and c-MET overexpression

    Non-small Cell Lung Cancer

34. Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

    Active, not recruiting Phase 3 Hansoh Pharma Started 2021Primary completion 2024-07 NCT04687241

    aumolertinib

    …bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

    Non-small Cell Lung Cancer

35. A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

    Recruiting Phase 3 Hansoh Pharma Started 2021Primary completion 2024-07 NCT04951635

    aumolertinib

    …rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19Del, L858R), either alone or in combination with other EGFR mutations including T790M, assess…

    Status may be outdated, last updated 2022-06-16Non-small Cell Lung Cancer

36. Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

    Enrolling by invitation Phase 3 Chinese Academy of Medical Sciences Started 2021Primary completion 2026-05 NCT04762459

    aumolertinibpemetrexedcisplatin

    …ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

    Status may be outdated, last updated 2022-02-24Non-small Cell Lung Carcinoma

37. A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

    Active, not recruiting Phase 3 AstraZeneca Started 2020Primary completion 2024-10 NCT04351555

    osimertinib FDA EUcisplatincarboplatinpemetrexed

    …ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (eg., T790M, G719X, Exo…

    Non-Small Cell Lung Cancer

38. Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

    Active, not recruiting Phase 3 Allist Pharmaceuticals Started 2019Primary completion 2021-09 NCT03787992

    furmonertinibgefitinib FDA EU

    …ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

    Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

39. A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

    Active, not recruiting Phase 3 AstraZeneca Started 2019Primary completion 2023-04 NCT04035486

    osimertinib FDA EUpemetrexedcarboplatincisplatin

    … with Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EG…

    Non-Small Cell Lung Cancer

40. A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

    Active, not recruiting Phase 3 AstraZeneca Started 2018Primary completion 2024-01 NCT03521154

    osimertinib FDA EU

    …rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by cobas® EGF…

    Non Small Cell Lung Cancer (Stage III)

41. A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

    Active, not recruiting Phase 3 Eli Lilly Started 2015Primary completion 2019-01 NCT02411448

    ramucirumab FDA EUerlotinib FDA EUgefitinib FDA EUosimertinib FDA EU

    …h erlotinib based on documented evidence of tumor harboring an activating EGFR mutation \[exon 19 deletion or exon 21 (L858R) substitution mutation\].

    Metastatic Non-Small Cell Lung Cancer

42. Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

    Active, not recruiting Phase 3 National Cancer Institute (NCI) Started 2015Primary completion 2025-12 NCT02193282

    erlotinib FDA EU

    Previously registered to A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation

    Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7

43. AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

    Active, not recruiting Phase 3 AstraZeneca Started 2015Primary completion 2022-04 NCT02511106

    osimertinib FDA EU

    …ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

    Stage IB-IIIA Non-small Cell Lung Carcinoma

44. Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy

    Not yet recruiting Phase 2 Fudan University Started 2026Primary completion 2030-09 NCT07822984

    Third-generation EGFR tyrosine kinase inhibitorpemetrexed

    Sensitizing EGFR mutation: EGFR exon 19 deletion or EGFR L858R.

    EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer)

45. A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

    Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026Primary completion 2028-01 NCT07548060

    sacituzumab tirumotecanfurmonertinib

    …er (AJCC)\], with tissue or blood-based genetic testing showing EGFR-sensitive mutations (19del and L858R).

    NSCLC Stage IV, EGFR Gene Mutation

46. Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

    Recruiting Phase 1/2 Second Affiliated Hospital of Nanchang University Started 2026Primary completion 2027-12 NCT07655622

    vebreltinibfurmonertinib

    …ed/metastatic disease Histologically or cytologically confirmed EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R point mutation)

    Non-Small-Cell Lung Cancer

47. Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer

    Recruiting Phase 2 Chinese University of Hong Kong Started 2026Primary completion 2029-03 NCT07379476

    osimertinib FDA EU

    Positive for EGFR exon 19 deletion or EGFR exon 21 L858R mutation (either by tissue or plasma testing)

    Lung Cancer (NSCLC)

48. Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

    Recruiting Phase 2 Massachusetts General Hospital Started 2026Primary completion 2028-03 NCT07405190

    ivonescimabcarboplatinpemetrexed

    …vonescimab monotherapy: Tumor harboring classical EGFR sensitizing mutation (i.e., L858R, exon 19 deletion), or ALK, ROS1, RET, or NTRK1-3 fusion, per local testing.

    Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell

49. Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

    Not yet recruiting Phase 2 Zhejiang Cancer Hospital Started 2026Primary completion 2027-06 NCT07343479

    sacituzumab tirumotecan

    … EGFR sensitizing mutation including exon 19 deletion (19-Del) or exon 21 point mutation (L858R);

    NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis

50. Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

    Recruiting Phase 2 AstraZeneca Started 2026Primary completion 2029-05 NCT07295821

    osimertinib FDA EU

    …arbors 1 of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M

    Lung Cancer

51. EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

    Recruiting Phase 2 Nanfang Hospital, Southern Medical University Started 2026Primary completion 2029-03 NCT07637448

    EGFR-TKIs Combined with PD-1 Monoclonal Antibody

    …atients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del/L858R) locally advanced or metastatic (stage IIIB/IIIC or IV) non-small cell lung cancer …

    Lung Cancer Non-Small Cell Cancer (NSCLC), EGFR Activating Mutation, PD-1 Antibody

52. Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

    Not yet recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2026Primary completion 2027-12 NCT07413952

    limertinib

    … or third-party testing institutions confirming the presence of EGFR classical mutations (19Del \& 21L858R).

    NSCLC

53. PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

    Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2026Primary completion 2027-12 NCT07416058

    iparomlimab and tuvonralimabpemetrexedbevacizumab

    these mutations are stratified as follows: EGFR (19del, L858R)

    Lung Adenocarcinoma

54. A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment

    Active, not recruiting Phase 2 Shandong Cancer Hospital and Institute Started 2026Primary completion 2028-01 NCT07669051

    ivonescimab

    …testing before enrollment, including exon 19 deletion (19Del) and exon 21 point mutation (L858R)

    NSCLC (Advanced Non-small Cell Lung Cancer)

55. Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

    Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026Primary completion 2028-01 NCT07505173

    osimertinib FDA EU

    …e test confirmed EGFR sensitive mutations, including exon 19 deletion (19del) and exon 21 L858R mutation (verified and confirmed by investigators at the respective study centers);

    Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases

56. Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

    Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026Primary completion 2030-12 NCT07298148

    furmonertinib

    Documented EGFR 19del or L858R mutation.

    NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer, EGFR-TKI Sensitizing Mutation

57. Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

    Recruiting Phase 2 Jonsson Comprehensive Cancer Center Started 2026Primary completion 2027-02 NCT07323641

    osimertinib FDA EUtelisotuzumab vedotin

    Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to osimertinib.

    Lung Non-Small Cell Carcinoma

58. Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

    Not yet recruiting Phase 2 Hunan Province Tumor Hospital Started 2026Primary completion 2027-12 NCT07001995

    limertinibetoposidecarboplatin

    …ologically confirmed non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation (exon 19 deletion or L858R, with or without concurrent mutations).

    Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC

59. Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

    Not yet recruiting Phase 1/2 Innovent Biologics Started 2026Primary completion 2027-06 NCT07612137

    IBI3005sintilimabbevacizumablimertinibosimertinib FDA EUcarboplatin

    Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology speci…

    Solid Tumor

60. Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

    Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2026Primary completion 2029-12 NCT07622706

    furmonertinib

    5.EGFR mutation-positive (19Del and/or L858R, with or without T790M) as determined by NGS testing of tumor tissue or bloo…

    NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy

61. Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

    Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026Primary completion 2027-05 NCT07551414

    Zorifertinib Plus Intra-Ommaya CSF Chemotherapy

    …all cell lung cancer (NSCLC) and test positive for EGFR-sensitive mutations (L858R and/or Exon 19Del).

    NSCLC (Non-small Cell Lung Carcinoma), Leptomeningeal Metastasis, EGFR-TKI Sensitizing Mutation, Zorifertinib

62. Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

    Not yet recruiting Phase 2 Zhou Chengzhi Started 2026Primary completion 2028-07 NCT07685197

    Presence of EGFR sensitizing mutations (exon 19 deletion or exon 21 L858R point mutation).

    NSCLC, EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, Trop2

63. JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2026Primary completion 2028-04 NCT07518160

    JS212

    Exon 19 deletion or L858R mutation,Either alone or in combination with other EGFR mutations, Including tho…

    Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

64. A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy

    Recruiting Phase 2 Samsung Medical Center Started 2026Primary completion 2029-06 NCT07774520

    Supplementation of magnesium lactateDose reduction of lezertinib

    Patient with a confirmed EGFR mutation of Exon 19 deletion or L858R.

    Non-small Cell Lung Cancer(NSCLC), EGFR Mutant

65. Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

    Not yet recruiting Phase 2 Jiangmen Central Hospital Started 2026Primary completion 2027-10 NCT07482605

    furmonertinib

    Positive for EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R).

    Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis

66. ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy

    Not yet recruiting Phase 2 Hebei Medical University Fourth Hospital Started 2026Primary completion 2030-02 NCT07410611

    befotertinib

    Presence of an EGFR sensitizing mutation (19Del or 21L858R);

    Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination

67. Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

    Not yet recruiting Phase 2 Guangzhou University of Traditional Chinese Medicine Started 2026Primary completion 2030-07 NCT07709585

    Befotinibpemetrexedcisplatincarboplatin

    Confirmed EGFR exon 19 deletion or exon 21 (L858R) substitution mutation by central laboratory or site-validated testing …

    Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 Mutation, EGFR Exon 21 L858R Mutation

68. Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

    Recruiting Phase 2 NYU Langone Health Started 2026Primary completion 2030-12 NCT07874490

    osimertinib FDA EUCyclosporine A (CsA)

    Somatic activating mutation in EGFR exon 19 deletion or EGFR L858R in pre-treatment tumor biopsy or cytology from pleural fluid or cfDNA as de…

    Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

69. Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)

    Not yet recruiting Phase 2 Yonsei University Started 2026Primary completion 2031-01 NCT07507188

    amivantamab FDA EUlazertinib FDA EUcarboplatinpemetrexed

    Documented activating EGFR mutation (Exon 19 deletion or L858R)

    Non Small Cell Lung Cancer

70. Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

    Recruiting Phase 2 Taipei Medical University Hospital Started 2026Primary completion 2028-12 NCT07624487

    aumolertinibpemetrexedcarboplatin

    Documentation of an EGFR L858R mutation is mandatory.

    Lung Adenocarcinoma Metastatic

71. Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

    Not yet recruiting Phase 1/2 Shanxi Province Cancer Hospital Started 2026Primary completion 2028-10 NCT07486648

    capivasertibosimertinib FDA EU

    Documented EGFR sensitive mutations (exon19 deletion, L858R mutation) prior to the first-line EGFR-TKI therapy.

    Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Advanced Non-small-cell Lung Cancer

72. Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

    Not yet recruiting Phase 2 Shanghai Chest Hospital Started 2025Primary completion 2026-03 NCT06688656

    pemetrexedcarboplatinsintilimab

    …ically, cytologically, or hematologically confirmed presence of EGFR-sensitive mutations (Ex19del, L858R), with co-existing driver mutations allowed;

    Lung Cancer

73. Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

    Recruiting Phase 2 Shanghai Junshi Bioscience Started 2025Primary completion 2026-09 NCT06868836

    JS207pemetrexedcarboplatincisplatinJS212

    … exon G719X mutation, 19 exon deletion mutation, 20 exon S768I or T790M mutation, 21 exon L858R or L861Q mutation), ALK fusion, ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET14 exon…

    Non-squamous Non-small Cell Lung Cancer

74. A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

    Recruiting Phase 2 Shanghai Chest Hospital Started 2025Primary completion 2029-01 NCT07058519

    osimertinib FDA EU

    …dvanced or metastatic non-squamous NSCLC with sensitizing EGFR mutations positive (either Exon 19 deletion or 21 L858R, confirmed by histology or cytology), and classified as stage IIIB, IIIC, IV …

    Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

75. High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

    Not yet recruiting Phase 2 Qiming Wang Started 2025Primary completion 2027-01 NCT06971406

    Combination therapy prospective cohort

    EGFR mutations confirmed by genetic testing (EGFR Ex19del/L858R/Ex20ins/PACC/L861Q).

    Non Small Cell Lung Cancer, EGFR Mutation, Leptomeningeal Metastases, Targeted Therapy

76. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    Recruiting Phase 1/2 BioNTech Started 2025Primary completion 2028-03 NCT07070232

    YL202pumitamigitraconazoleparoxetine

    …est results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).

    Advanced Solid Tumor

77. Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

    Recruiting Phase 1/2 Peking University Cancer Hospital & Institute Started 2025Primary completion 2027-04 NCT07087223

    vebreltinibfurmonertinib

    Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

    Non Small Cell Lung Cancer NSCLC

78. A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

    Not yet recruiting Phase 2 Shanghai Chest Hospital Started 2025Primary completion 2026-12 NCT06982924

    limertinibbevacizumab

    Confirmed EGFR - sensitive mutations (Ex19del, L858R) in tumor histology or cytology or in hematology.

    EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive

79. ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

    Recruiting Phase 2 Fudan University Started 2025Primary completion 2026-12 NCT06775743

    ORIENT-31 regimen

    EGFR-sensitive mutations (L858R, 19del);

    NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

80. Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)

    Recruiting Phase 2 Pusan National University Hospital Started 2025Primary completion 2030-06 NCT07073365

    Presence of activating EGFR mutation (exon 19 deletion or L858R).

    Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor

81. A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

    Recruiting Phase 1/2 Bristol Myers Squibb Started 2025Primary completion 2031-02 NCT06618287

    izalontamab brengitecanosimertinib FDA EUpembrolizumabnivolumabpumitamig

    …ants must have pathologically confirmed locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or L858R mutation in exon 21, either alone or in combination with other EGFR mutations, w…

    Lung Cancer, Breast Cancer

82. JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

    Active, not recruiting Phase 1/2 Suzhou Junjing BioSciences Started 2025Primary completion 2028-07 NCT06940401

    JS111 capsules (AP-L1898)

    Confirmed presence of EGFR-sensitizing mutations (exon 19 deletion or L858R mutation), either alone or co-occurring with other EGFR mutations (including T79…

    NSCLC

83. Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

    Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2025Primary completion 2026-12 NCT06890182

    furmonertinibcarboplatincisplatinpemetrexed

    EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

    Non-small Cell Lung Cancer

84. Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

    Recruiting Phase 2 Betta Pharmaceuticals Started 2025Primary completion 2028-11 NCT07181499

    befotertinibpemetrexedcarboplatin

    …FR TKIs, with EGFR-sensitive mutations confirmed via tissue or blood samples (defined as: 19 Del or 21 L858R);

    NSCLC, Adjuvant Drug Therapy, EGFR

85. Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

    Recruiting Phase 2 Sun Yat-sen University Started 2025Primary completion 2025-12 NCT06924398

    Postoperative EGFR-TKI Therapy

    …ide of the lung, with pathology confirming adenocarcinoma and an EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R point mutation).

    Lung Cancer (NSCLC)

86. Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

    Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2025Primary completion 2028-12 NCT07304739

    furmonertinibIntrathecal chemotherapy

    … patient was confirmed by a local laboratory to have one of the following EGFR mutations :19Del or L858R;

    Non Small Cell Lung Cancer

87. Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

    Not yet recruiting Phase 2 Fudan University Started 2025Primary completion 2026-07 NCT07193160

    sacituzumab tirumotecanfurmonertinib

    …ious EGFR mutation test results (known presence of EGFR mutations sensitive to EGFR-TKI \[Ex19del, L858R\], which may exist alone or concurrently with other EGFR mutations, possibly inclu…

    NSCLC (Non-small Cell Lung Cancer)

88. Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

    Not yet recruiting Phase 2 The University of Hong Kong Started 2025Primary completion 2027-12 NCT06918782

    osimertinib FDA EU

    Confirmed EGFR common sensitizing mutations (exon 21 L858R or exon 19 del) by locally approved molecular testing methods (allele-specific PCR or NGS) based on tumo…

    Lung Cancer (NSCLC)

89. Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

    Recruiting Phase 2 Guangzhou Medical University Started 2025Primary completion 2026-01 NCT06296745

    pemetrexed

    …ytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).

    Leptomeningeal Metastasis

90. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

    Recruiting Phase 2 RemeGen Started 2025Primary completion 2026-05 NCT06962865

    RC108furmonertinib

    Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;

    Non-Small Cell Lung Cancer

91. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

    Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025Primary completion 2028-06 NCT07079475

    DZD6008sunvozertinibosimertinib FDA EU

    Part B: EGFR sensitizing mutations (Exon19del and/or L858R) with or without T790M/C797S resistance mutations.

    Non-Small Cell Lung Cancer

92. Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

    Recruiting Phase 2 Sehhoon Park Started 2025Primary completion 2027-03 NCT06830694

    atezolizumabetoposidecarboplatin

    Patient initially diagnosed with activating EGFR mutation (L858R, Del 19) and treated with any kind of EGFR TKI.

    Small Cell Carcinoma of Lung

93. Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

    Not yet recruiting Phase 2 Betta Pharmaceuticals Started 2025Primary completion 2028-04 NCT06885840

    MCLA-129

    …Cohort 2: Patients with advanced NSCLC with previously detected EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation) who have progressed after prior standard treatment which inclu…

    Non-Small Cell Lung Cancer

94. Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

    Not yet recruiting Phase 2 Li-kun Chen Started 2025Primary completion 2027-12 NCT07197008

    sacituzumab tirumotecanbevacizumab

    Histologically or cytologically confirmed nonsquamous NSCLC with EGFR-sensitive mutation (exon 19 deletion or exon 21 L858R mutation).

    Lung Cancer

95. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    Recruiting Phase 1/2 BioNTech Started 2025Primary completion 2028-11 NCT07111520

    YL202pumitamig

    …est results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).

    Non-small Cell Lung Cancer

96. A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy

    Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2025Primary completion 2028-06 NCT07375316

    osimertinib FDA EUsacituzumab tirumotecan

    Presence of sensitizing EGFR mutation (exon 19 deletion and/or L858R);

    Non Small Cell Lung Cancer

97. A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

    Not yet recruiting Phase 2 Innovent Biologics Started 2025Primary completion 2026-09 NCT07124793

    IBI363

    Documented EGFR mutation (ex19del or L858R) detected in tumor tissue or blood samples;

    EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

98. Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

    Not yet recruiting Phase 2 Peking Union Medical College Hospital Started 2024Primary completion 2027-01 NCT06752408

    aumolertinibosimertinib FDA EU

    … effusion, ascites, cerebrospinal fluid) with at least one sensitizing mutation (L858R or 19Del).

    Non Small Cell Lung Cancer

99. Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction

    Not yet recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2027-10 NCT06604351

    sintilimabnab-paclitaxelcarboplatin

    …all cell lung cancer (NSCLC) without prior systemic therapy and EGFR-sensitive mutations (19del, L858R and T790M).

    Status may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer

100. Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

     Active, not recruiting Phase 2 Guangdong Provincial People's Hospital Started 2024Primary completion 2026-01 NCT06300424

     aumolertinibcarboplatinnab-paclitaxel

     6. harboring EGFR mutation: Ex19del, L858R, T790M, G719X, Exon20 insertions, S768I or L861Q

     Non Small Cell Lung Cancer, EGFR Gene Mutation

101. Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

     Recruiting Phase 2 Avistone Biotechnology Started 2024Primary completion 2026-10 NCT06574347

     vebreltinibosimertinib FDA EUPLB1004

     Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .

     Non-Small-Cell Lung Cancer

102. To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

     Active, not recruiting Phase 2 AstraZeneca Started 2024Primary completion 2026-07 NCT06194448

     osimertinib FDA EUcisplatincarboplatinpemetrexedpaclitaxelRadiation

     …rs one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo T790M

     Lung Cancer

103. Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

     Active, not recruiting Phase 2 National Cancer Center Started 2024Primary completion 2026-09 NCT06827145

     vebreltinibosimertinib FDA EU

     4.EGFR 21 L858R mutation.

     Non-Small-Cell Lung Cancer

104. Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

     Not yet recruiting Phase 2 Fujian Cancer Hospital Started 2024Primary completion 2028-04 NCT06441045

     Double Dose of Third-generation EGFR-TKIpemetrexed

     with EGFR sensitive mutation (exon 19 deletion or L858R mutation), LM progression after conventional doses of three generation EGFR targ…

     Status may be outdated, last updated 2024-06-04Leptomeningeal Metastasis

105. Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

     Not yet recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Started 2024Primary completion 2029-06 NCT06436144

     osimertinib FDA EUetoposide

     Harboring an EGFR sensitizing mutation (Exon 19 deletion or L858R).

     Status may be outdated, last updated 2024-05-30Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV

106. A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

     Recruiting Phase 1/2 Voronoi Started 2024Primary completion 2029-01 NCT07699328

     VRN110755

     NSCLC with EGFR exon 19 deletion or L858R mutation plus a C797X resistance mutation following disease progression after fi…

     EGFR-Mutant Non-Small Cell Lung Cancer

107. Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

     Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2024Primary completion 2027-12 NCT06452433

     glumetinibosimertinib FDA EUaumolertinibfurmonertinib

     Patients with EGFR mutations known to be associated with drug sensitivity (i.e., exon 19 deletion or L858R mutation).

     Status may be outdated, last updated 2024-06-11Non-small Cell Lung Cancer

108. Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

     Not yet recruiting Phase 1/2 Henan Cancer Hospital Started 2024Primary completion 2026-07 NCT06454890

     Anti-Trop2 CAR-NK cell

     For patients with EGFR-sensitive mutations (19del, 21L858R, 18exonG719X, 20exonS768I, 21exonL861Q), they must meet one of the following req…

     Status may be outdated, last updated 2024-06-12Non-Small Cell Lung Cancer NSCLC

109. Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study

     Active, not recruiting Phase 2 Li-kun Chen Started 2024Primary completion 2028-02 NCT06728865

     befotertinibbevacizumab

     Baseline evaluation confirming the presence of EGFR-sensitizing mutations (19del/L858R) via first- or second-generation sequencing.

     Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases

110. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

     Recruiting Phase 2 Abbisko Therapeutics Started 2024Primary completion 2027-12 NCT06668103

     furmonertinib

     Documented genetic testing reports confirmed the presence of EGFR L858R or EGFR exon 19 del mutations in tumor or plasma ctDNA.

     Non-Small Cell Lung Cancer With EGFR Mutation

111. Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

     Recruiting Phase 1/2 Pierre Fabre Medicament Started 2024Primary completion 2027-11 NCT06567015

     STX-241

     Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th editi…

     Non-small Cell Lung Cancer (NSCLC)

112. Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

     Recruiting Phase 2 Sehhoon Park Started 2024Primary completion 2029-09 NCT06106802

     lazertinib FDA EUtepotinib

     Confirmed EGFR mutations (exon 19 deletion, L858R) with acquired resistance after first-line lazertinib treatment (either partial re…

     Non-Small Cell Lung Cancer Metastatic

113. Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)

     Active, not recruiting Phase 2 Tang-Du Hospital Started 2023Primary completion 2025-09 NCT05430802

     furmonertinibpemetrexed

     EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

     Non-small Cell Lung Cancer

114. Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

     Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2023Primary completion 2025-03 NCT05778149

     aumolertinibanlotinib

     Locally advanced or metastatic NSCLC EGFR sensitive mutations (19del and L858R) and TP53 co-mutation;

     Status may be outdated, last updated 2023-03-21Aumolertinib, Anlotinib, TP53, NSCLC

115. A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

     Recruiting Phase 2 Taiho Pharmaceutical Started 2023Primary completion 2028-08 NCT05967689

     zipalertinibCYP CocktailTransporter Cocktail

     common EGFRmt (eg, ex19del or L858R)

     Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

116. A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

     Active, not recruiting Phase 1/2 Johnson & Johnson Started 2023Primary completion 2027-01 NCT05908734

     Cetrelimabamivantamab FDA EU

     Cohort A: Participant's tumor must have an EGFR exon19del or L858R mutation, as determined by local molecular testing, Cohort B: Participants must …

     Carcinoma, Non-Small-Cell Lung

117. SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

     Active, not recruiting Phase 2 Fudan University Started 2023Primary completion 2027-08 NCT06020066

     EGFR-TK Inhibitor

     EGFR mutations: EGFR L858R, EGFR exon 19 deletion;

     Brain Metastases, Non-small Cell Lung Cancer

118. Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

     Recruiting Phase 2 Shanghai Zhongshan Hospital Started 2023Primary completion 2028-08 NCT05987826

     furmonertinib

     7）EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)

     Non-Small Cell Lung Cancer

119. Premedication to Reduce Amivantamab Associated Infusion Related Reactions

     Active, not recruiting Phase 2 Johnson & Johnson Started 2023Primary completion 2024-03 NCT05663866

     dexamethasoneMontelukastmethotrexateamivantamab FDA EUlazertinib FDA EU

     Previously identified EGFR-mutated non-small cell lung cancer (NSCLC) (EGFR Exon19 deletion or L858R) (identified locally in a Clinical Laboratory Improvement Amendments \[CLIA\]-ce…

     Carcinoma, Non-Small-Cell Lung

120. First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

     Active, not recruiting Phase 1/2 Bridge Biotherapeutics Started 2023Primary completion 2026-08 NCT05920135

     BBT-207

     …that the tumor harbors an EGFR mutation known to be associated with EGFR TKI sensitivity (exon 19 deletion or L858R).

     EGFR Mutant Advanced Non-Small Cell Lung Cancer

121. A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

     Recruiting Phase 2 National Cancer Center, Korea Started 2023Primary completion 2026-09 NCT06156527

     lazertinib FDA EUbevacizumab

     Patients with institutionalized EGFR mutation (exon 19 deletion or L858R)

     Status may be outdated, last updated 2023-12-05Lazertinib

122. A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

     Active, not recruiting Phase 2 AstraZeneca Started 2023Primary completion 2029-11 NCT05526755

     osimertinib FDA EU

     …on by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR …

     Stage II-IIIB Non-small Cell Lung Carcinoma

123. Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer

     Active, not recruiting Phase 2 Yonsei University Started 2022Primary completion 2028-05 NCT06268210

     lazertinib FDA EUpemetrexedcarboplatin

     Documented presence of EGFR activating mutations (EGFR exon 19 deletion or L858R mutation).

     Non-small Cell Lung Cancer

124. To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

     Recruiting Phase 2 OBI Pharma Started 2022Primary completion 2025-12 NCT05442060

     30 μg OBI-833/100 μg OBI-821erlotinib FDA EU

     The tumor harbors an exon 19 deletion or exon 21 L858R mutation in EGFR, confirmed locally.

     Non-small Cell Lung Cancer

125. Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy

     Recruiting Phase 2 Konkuk University Medical Center Started 2022Primary completion 2024-05 NCT05469022

     lazertinib FDA EU

     …th the following EGFR gene mutations in the test on bronchoalveolar lavage fluid: E19Del, L858R alone or concurrent rare EGFR gene mutations (T790M, G719X, exon 20 insertion, S768I)

     Status may be outdated, last updated 2022-07-21Non Small Cell Lung Cancer

126. Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

     Not yet recruiting Phase 2 Liaoning Cancer Hospital & Institute Started 2022Primary completion 2024-07 NCT05132985

     icotinibcisplatincarboplatinpemetrexed

     A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone

     Status may be outdated, last updated 2021-12-10NSCLC, EGF-R Positive Non-Small Cell Lung Cancer

127. Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

     Recruiting Phase 2 Samsung Medical Center Started 2022Primary completion 2027-09 NCT04591002

     osimertinib FDA EU

     …ed lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.

     Lung Cancer

128. Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

     Recruiting Phase 2 Sun Yat-sen University Started 2022Primary completion 2025-02 NCT05334277

     furmonertinibpemetrexedcarboplatinbevacizumab

     Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically and confirmed by ctDNA, the r…

     Status may be outdated, last updated 2022-08-31Non-small Cell Lung Cancer

129. Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

     Recruiting Phase 2 Guangdong Association of Clinical Trials Started 2022Primary completion 2025-10 NCT05536505

     Adjuvant treatment for MRD positivity

     Target population is completely resected pathological stage IB-IIIB NSCLC with EGFR exon 19 deletions, L861Q mutation, G719X mutation and exon 21 L858R activating mutation.

     Status may be outdated, last updated 2022-09-14MRD

130. Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

     Recruiting Phase 2 Samsung Medical Center Started 2022Primary completion 2027-09 NCT05528458

     osimertinib FDA EU

     …ed lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion.

     Lung Adenocarcinoma

131. First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

     Recruiting Phase 1/2 Shanghai Chest Hospital Started 2022Primary completion 2025-01 NCT05271916

     dacomitinib FDA EUanlotinib

     It is acceptable for subjects with the presence of EGFR activating mutation (exon 19 deletion and the L858R mutation in exon 21) to be included in this Phase I study

     Status may be outdated, last updated 2023-04-19Non-Small Cell Lung Cancer (NSCLC)

132. Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

     Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2022Primary completion 2024-10 NCT05686434

     osimertinib FDA EU

     …ns one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;

     Status may be outdated, last updated 2023-01-17NSCLC, Stage I

133. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

     Recruiting Phase 2 Johnson & Johnson Started 2022Primary completion 2027-08 NCT05498428

     amivantamab FDA EUlazertinib FDA EUcarboplatinpemetrexedDirect Oral Anticoagulant (DOAC)Low Molecular Weight Heparin (LMWH)

     …quirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation

     Carcinoma, Non-small-Cell Lung

134. Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

     Active, not recruiting Phase 1/2 Jonsson Comprehensive Cancer Center Started 2021Primary completion 2026-12 NCT04285671

     necitumumabosimertinib FDA EUtrastuzumab

     Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to EGFR tyrosine k…

     Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8

135. A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

     Recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2021Primary completion 2024-03 NCT05104788

     icotinibcisplatincarboplatinpemetrexed

     …d with EGFR-TKI （epidermal growth factor receptor tyrosine kinase inhibitors）sensitivity (Ex19del, L858R).

     Status may be outdated, last updated 2021-11-03Non-Small Cell Lung Cancer

136. HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

     Active, not recruiting Phase 2 Daiichi Sankyo Started 2021Primary completion 2022-11 NCT04619004

     patritumab deruxtecan

     Documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R.

     Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

137. Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

     Recruiting Phase 2 Goethe University Started 2021Primary completion 2025-11 NCT05281406

     osimertinib FDA EUpemetrexedcisplatincarboplatin

     Tumor positive for Ex19del or L858R EGFR mutation assessed according to local standard.

     NSCLC Stage IIIB, NSCLC Stage IV

138. Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

     Recruiting Phase 2 Sun Yat-sen University Started 2021Primary completion 2023-09 NCT05011487

     osimertinib FDA EUcisplatinpemetrexed

     …ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations (ie, T790M, G719X, Exon…

     Status may be outdated, last updated 2024-01-16Non-Small Cell Lung Cancer

139. A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

     Active, not recruiting Phase 2 Shanghai Chest Hospital Started 2021Primary completion 2025-12 NCT05078931

     pembrolizumablenvatinib

     Have confirmation with sensitizing EGFR mutations, either DEL19 or L858R

     NSCLC

140. Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

     Recruiting Phase 2 National Taiwan University Hospital Started 2021Primary completion 2026-10 NCT05215548

     afatinib FDA EU

     Patients must have one of the following:NSCLC which harbors EGFR exon 19 deletion or L858R mutation.

     NSCLC Stage IV

141. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

     Recruiting Phase 1/2 Vivace Therapeutics Started 2021Primary completion 2029-11 NCT04665206

     VT3989nivolumabipilimumabosimertinib FDA EUpemetrexedcarboplatin

     … diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.

     Solid Tumor, Adult, Mesothelioma, NSCLC

142. Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

     Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2020Primary completion 2024-06 NCT03831932

     osimertinib FDA EUTelaglenastat Hydrochloride

     Activating mutation present in the EGFR gene (L858R or exon 19 deletion, alone or in combination with other EGFR mutations) as per local assessment of a tissue b…

     Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

143. Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

     Active, not recruiting Phase 2 Shanghai Chest Hospital Started 2020Primary completion 2022-12 NCT04504071

     dacomitinib FDA EU

     Mutation in exon 19:

     Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer

144. Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

     Active, not recruiting Phase 2 University of California, San Diego Started 2020Primary completion 2025-12 NCT04545710

     abemaciclibosimertinib FDA EU

     Tumor must harbor an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q).

     Status may be outdated, last updated 2024-08-05Lung Cancer

145. Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

     Active, not recruiting Phase 2 British Columbia Cancer Agency Started 2019Primary completion 2025-04 NCT03769103

     osimertinib FDA EU

     Epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGF…

     Lung Cancer Non-small Cell Stage IV, Brain Metastases

146. Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

     Active, not recruiting Phase 2 Fox Chase Cancer Center Started 2019Primary completion 2026-12 NCT03786692

     Arm AArm B

     Must have either tumors that harbor an EGFR mutation in exon 19 or exon 21, or must be never smoker wild-types.

     Non-Small Cell Carcinoma of Lung, TNM Stage 4

147. Phase 2 Study of Dacomitinib in NSCLC

     Active, not recruiting Phase 2 National Cancer Centre, Singapore Started 2019Primary completion 2026-03 NCT04027647

     dacomitinib FDA EU

     The presence of an EGFR activating mutation (exon 19 deletion or the L858R mutation in exon 21) in tumor specimen determined by the local laboratory;

     NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV, Recurrent NSCLC

148. Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

     Active, not recruiting Phase 2 Xiuning Le Started 2019Primary completion 2026-12 NCT03909334

     osimertinib FDA EUramucirumab FDA EU

     NSCLC which harbours EGFR Exon 19 deletion.

     Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer

149. A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

     Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2018Primary completion 2027-06 NCT03392246

     osimertinib FDA EUselumetinib

     …e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory.

     Non-small Cell Lung Cancer

150. Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2022-12 NCT06385483

     afatinib FDA EU

     Activating mutations of EGFR (del 19, L858R) OR

     Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm

151. Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

     Active, not recruiting Phase 2 University of California, San Francisco Started 2018Primary completion 2023-01 NCT03433469

     osimertinib FDA EU

     Documented activating EGFR mutation (Exon 19 deletion, T790M, or L858R) on tumor samples by Clinical Laboratory Clinical Laboratory Improvement…

     Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer

152. Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

     Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2018Primary completion 2027-04 NCT03410043

     osimertinib FDA EU

     NSCLC which harbors EGFR exon 19 deletion or L858R mutation.

     Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

153. Osimertinib In EGFR Mutant Lung Cancer

     Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2018Primary completion 2028-02 NCT03586453

     osimertinib FDA EU

     …e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory from tumor tissue.

     Carcinoma, Non-Small-Cell Lung

154. Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2025-02 NCT02971501

     bevacizumabosimertinib FDA EU

     Non-small cell lung cancer (NSCLC) with an activating EGFR mutation (exon 19 deletion, L858R point mutation, or any other mutation known to be associated with EGFR TKI sensiti…

     Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8

155. Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

     Active, not recruiting Phase 1/2 Dana-Farber Cancer Institute Started 2017Primary completion 2026-10 NCT03122717

     gefitinib FDA EUosimertinib FDA EU

     …e histologically confirmed stage IV NSCLC (per AJCC 7th edition) with either the L858R or exon 19 deletion activating EGFR mutation as identified in a CLIA-approved laboratory.

     Non-Small Cell Lung Cancer

156. An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

     Not yet recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026Primary completion 2027-01 NCT07461727

     EDB-102

     …bility of tumor tissue obtained after progression on third-generation EGFR-TKI, with EGFR L858R mutation confirmed in the post-progression tumor tissue or blood sample by central labora…

     Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Liver Metastases, EGFR Gene Mutation

157. JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure

     Not yet recruiting Phase 1 Yonsei University Started 2026Primary completion 2028-06 NCT07798921

     amivantamab FDA EU

     Subjects with advanced and/or metastatic NSCLC harboring an activating EGFR mutation (Ex19del or L858R), as confirmed by testing of tissue or blood samples, whose disease has progress…

     Carcinoma, Non-Small-Cell Lung

158. JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC

     Not yet recruiting Phase 1 Biotech Pharmaceutical Started 2026Primary completion 2028-05 NCT07582822

     JH021

     …nced or metastatic non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations (EGFR exon 19 deletion or exon 21 L858R) detected in tumor tissue or plasma ctDNA, who are resistant to third-ge…

     Advanced Solid Tumor

159. OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

     Recruiting Phase 1 M.D. Anderson Cancer Center Started 2026Primary completion 2028-06 NCT07655583

     Exon 19 deletion

     Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy

160. A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

     Recruiting Phase 1 Dizal Pharmaceuticals Started 2025Primary completion 2027-09 NCT06905197

     DZD6008sunvozertinib

     For Part A monotherapy cohorts and all cohorts of Part B, EGFR sensitizing mutations (Exon19del and/or L858R) are required.

     Non Small Cell Lung Cancer

161. A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC

     Recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2025-10 NCT06926413

     aumolertinibmidazolam

     …nti-tumor systemic therapy, and the tumor must harbor at least one of the EGFR mutations (ex19del or L858R, single mutation or combined with other EGFR mutations are both acceptable).

     Non Small Cell Lung Cancer

162. A Phase I Study of CFT8919 in Patients With Advanced NSCLC

     Recruiting Phase 1 Betta Pharmaceuticals Started 2024Primary completion 2027-06 NCT06641609

     CFT8919

     …rmed locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the EGFR-L858R mutation, who have failed standard treatment (disease progression or intolerance), lack s…

     Non-Small Cell Lung Cancer With EGFR Mutation

163. Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

     Not yet recruiting Phase 1 Jonathan Riess Started 2024Primary completion 2025-01 NCT06067776

     cetuximabosimertinib FDA EUtucatinib

     NSCLC must harbor at least one of the following EGFR activating mutations: Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, Exon 20 S768I.

     Status may be outdated, last updated 2023-10-05Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

164. A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

     Recruiting Phase 1 Hansoh Pharma Started 2024Primary completion 2025-08 NCT07130916

     aumolertinib

     …nti-tumor systemic therapy, and the tumor must harbor at least one of the EGFR mutations (ex19del or L858R).

     Non-Small Cell Lung Cancer

165. Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

     Recruiting Phase 1 Dizal Pharmaceuticals Started 2024Primary completion 2027-10 NCT06813365

     DZD6008

     Documentation of EGFR sensitizing mutation (Exon19del and/or L858R) from a local CLIA-certified laboratory (or equivalent).

     Nonsmall-cell Lung Cancer

166. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

     Recruiting Phase 1 Baili-Bio / SystImmune Started 2023Primary completion 2030-04 NCT05983432

     izalontamab brengitecan

     a) Evidence of documented EGFR TKI-sensitizing deletion mutation in EGFR Exon 19 (ex19del) or leucin-arginine substitution point mutation in EGFR Exon 21 (ex21L858R), the serine-i…

     Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer

167. Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

     Not yet recruiting Phase 1 Betta Pharmaceuticals Started 2023Primary completion 2028-11 NCT06015568

     MCLA-129befotertinib

     …astatic NSCLC that is not suitable for radical surgery or radiotherapy, and harbored EGFR exon 19 deletion or exon 21 L858R mutation( either alone or in combination with other EGFR mutations) in N…

     Status may be outdated, last updated 2023-08-29Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

168. A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

     Active, not recruiting Phase 1 M.D. Anderson Cancer Center Started 2023Primary completion 2028-01 NCT05704634

     cemiplimabKevzara (Sarilumab)

     NSCLC which harbours EGFR Exon 19 deletion.

     Lung Cancer

169. A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

     Active, not recruiting Phase 1 MediLink Therapeutics Started 2022Primary completion 2026-12 NCT05653752

     YL202

     Have a documentation of an EGFR-activating mutation (exon 19 deletion or L858R) detected from tumor tissue at diagnosis or thereafter.

     Non Small Cell Lung Cancer, Breast Cancer

170. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

     Recruiting Phase 1 BioNTech Started 2022Primary completion 2030-02 NCT05142189

     BNT116cemiplimabdocetaxelcarboplatinpaclitaxelgotistobartanti-B7-H3 antibody conjugated to topoisomerase I inhibitoranti-HER3 antibody conjugated to topoisomerase I inhibitorBispecific antibody for PD-L1 and VEGF-Aosimertinib FDA EUALK-inhibitor or RET-inhibitor

     Participants' NSCLC must have classical EGFR mutations, i.e., ex19Del or L858R.

     Non-Small Cell Lung Cancer

171. A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer

     Active, not recruiting Phase 1 Nalo Therapeutics Started 2022Primary completion 2025-06 NCT05514496

     NX-019

     Patients with NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations who have progressed on or after prior EGFR TKI therapy.

     EGFR Mutation-Related Tumors

172. Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

     Active, not recruiting Phase 1 City of Hope Medical Center Started 2022Primary completion 2027-10 NCT05166616

     osimertinib FDA EUTriptolide Analog

     … with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) sensitivity (Ex19del or L858R), either alone or in combination with other epidermal growth factor receptor (EG…

     Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8

173. Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

     Recruiting Phase 1 Ohio State University Comprehensive Cancer Center Started 2022Primary completion 2026-12 NCT04780568

     osimertinib FDA EUTegavivint

     A common activating mutation must be present in the EGFR gene, i.e., exon 19 deletion or L858R.

     Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

174. Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

     Recruiting Phase 1 Jiangsu Aosaikang Pharmaceutical Started 2022Primary completion 2026-12 NCT05306132

     ASKC202limertinib

     …ocally advanced or metastatic NSCLC;b)Histologically confirmed EGFR sensitizing mutation (Ex19del or L858R).；c)Disease progression following treatment with a third-generation EGFR TKI, or…

     Advanced Solid Tumor

175. Intrathecal Double Checkpoint Inhibition

     Active, not recruiting Phase 1 University of Zurich Started 2022Primary completion 2025-12 NCT05598853

     nivolumabipilimumab

     …ncogenic driver alteration: sensitising Epidermal Growth Factor Receptor (EGFR) mutation (exon 19-del and 21-L858R), anaplastic lymphoma kinase (ALK) or ROS proto-oncogene-1 (ROS1) rearrangem…

     Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV

176. HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

     Active, not recruiting Phase 1 Daiichi Sankyo Started 2021Primary completion 2025-01 NCT04676477

     patritumab deruxtecanosimertinib FDA EU

     Documentation of EGFR exon 19 deletion or L858R mutation detected from tumor tissue

     Non-Small Cell Lung Cancer (NSCLC)

177. A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

     Active, not recruiting Phase 1 Johnson & Johnson Started 2019Primary completion 2027-02 NCT04077463

     lazertinib FDA EUamivantamab FDA EUcarboplatinpemetrexed

     …Cohort D, E, and F: Participant must have advanced or metastatic EGFR-mutated NSCLC (EGFR Exon19 deletion or L858R) that has progressed on prior treatment with osimertinib in the first or second …

     Carcinoma, Non-Small-Cell Lung

178. Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

     Active, not recruiting Phase 1 Novartis Started 2018Primary completion 2026-10 NCT03333343

     nazartinibtrametinibribociclibnaporafenibcapmatinibgefitinib FDA EU

     …tologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.

     EGFR-mutant Non-small Cell Lung Cancer

179. U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

     Active, not recruiting Phase 1 Daiichi Sankyo Started 2017Primary completion 2025-12 NCT03260491

     patritumab deruxtecan

     …with EGFR tyrosine kinase inhibitor (TKI) sensitivity (including G719X, exon 19 deletion, L858R, L861Q)

     Non-Small Cell Lung Cancer (NSCLC)

180. Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

     Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2017Primary completion 2027-02 NCT02503722

     osimertinib FDA EUSapanisertib

     NSCLC must harbor an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion)

     Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7

181. Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

     Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2016Primary completion 2027-06 NCT02496663

     necitumumabosimertinib FDA EU

     NSCLC must harbor at least one of the following EGFR activating mutations: Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q or for EGFR Exon 20 insertion expansion cohort D, NSCLC mus…

     Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

182. Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

     Active, not recruiting Phase 1 Johnson & Johnson Started 2016Primary completion 2026-12 NCT02609776

     amivantamab FDA EUlazertinib FDA EUcarboplatinpemetrexed

     …ion Dose Escalation with lazertinib only: Participants must have been diagnosed with EGFR Exon 19del or L858R activating mutation and (a) be treatment naïve for metastatic disease, without a…

     Non-Small-Cell Lung Cancer

183. A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

     Active, not recruiting Phase 1 AbbVie Started 2014Primary completion 2026-08 NCT02099058

     osimertinib FDA EUnivolumabtelisotuzumab vedotinerlotinib FDA EU

     …ced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resi…

     Advanced Solid Tumors Cancer

184. Therapy for Advanced NSCLC With EGFR 19delins Mutation

     Not yet recruiting Early Phase 1 Fuzhou General Hospital Started 2026Primary completion 2030-10 NCT07458919

     icotinibgefitinib FDA EUbefotertinibosimertinib FDA EUfurmonertinib

     Epidermal growth factor receptor (EGFR) exon 19 deletion-insertion mutation (19delins) documented by testing of tumor tissue or plasma samples usi…

     Lung Cancer

185. Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

     Recruiting No phase Guangzhou University of Traditional Chinese Medicine Started 2026Primary completion 2028-09 NCT07348965

     furmonertinib

     Patients with EGFR exon 19 deletion or exon 21 L858R mutation

     NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation

186. JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

     Not yet recruiting No phase Huan Zhou Started 2026Primary completion 2026-11 NCT07714304

     JS212JS111 capsules (AP-L1898)

     Confirmed EGFR-sensitizing mutation, defined as an exon 19 deletion or L858R mutation, either occurring alone or together with other EGFR mutations, includin…

     NSCLC Harboring EGFR Mutations

187. MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC

     Not yet recruiting No phase Peking University People's Hospital Started 2026Primary completion 2030-10 NCT07873086

     aumolertinibpemetrexedcarboplatin

     EGFR exon 19 deletion and/or exon 21 L858R mutation detected by histological or cytological testing.

     Non-Small Cell Lung Cancer

188. Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

     Recruiting No phase Second Affiliated Hospital of Nanchang University Started 2026Primary completion 2027-12 NCT07398599

     bevacizumab

     Presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

     Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer

189. MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer

     Not yet recruiting No phase Shanghai Chest Hospital Started 2025Primary completion 2028-12 NCT06969781

     TKI

     EGFR exon 19 deletion or exon 21 L858R mutation.

     Lung Cancer (NSCLC)

190. EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

     Recruiting No phase Dana-Farber Cancer Institute Started 2025Primary completion 2027-09 NCT06716580

     Family history of EGFR positive LC L858R or exon 19

     Lung Cancer, EGFR Gene Mutation

191. Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

     Recruiting No phase Guangzhou Medical University Started 2024Primary completion 2026-06 NCT06304441

     osimertinib FDA EUpemetrexed

     …ytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del).

     Leptomeningeal Metastasis

192. A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

     Recruiting No phase Intergroupe Francophone de Cancerologie Thoracique Started 2024Primary completion 2031-10 NCT06053099

     Presence of a common EGFR mutation (Del19 or L858R).

     Status may be outdated, last updated 2024-03-08Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R

193. The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

     Not yet recruiting No phase Zhejiang University Started 2024Primary completion 2026-12 NCT06287593

     Patients with EGFR 19del or L858R mutations.

     Status may be outdated, last updated 2024-04-24EGF-R Positive Non-Small Cell Lung Cancer

194. Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)

     Not yet recruiting No phase Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo Started 2023Primary completion 2026-11 NCT05998993

     Have confirmation of the presence of common EGFR mutations (exon 19 deletion, L858R/exon 21, or G719X) through any locally and internationally accepted standard tests…

     Status may be outdated, last updated 2023-08-21EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Exon 21 Mutation

195. A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

     Recruiting No phase Kunming Medical University Started 2023Primary completion 2026-10 NCT06102928

     anlotinibaumolertinib

     … IIIB, IIIC, or IV) confirmed by histology or cytology, with the presence of EGFR 21 exon L858R mutation in the driving gene

     Status may be outdated, last updated 2023-10-26Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

196. A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

     Recruiting No phase Hadassah Medical Organization Started 2021Primary completion 2024-12 NCT05033691

     L858R (exon 21)

     Status may be outdated, last updated 2021-09-05NSCLC, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer

197. Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

     Active, not recruiting No phase Seoul National University Hospital Started 2019Primary completion 2026-09 NCT03969823

     osimertinib FDA EU

     …diotherapy with local confirmation of the presence of EGFR TKI-sensitizing mutation (EGFR exon 19 deletion or L858R mutation), either alone or in combination with other EGFR mutations excluding EG…

     Locally Advanced or Metastatic NSCLC

198. An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

     Recruiting Phase 4 AstraZeneca Started 2026Primary completion 2028-01 NCT07357597

     dexamethasonedatopotamab deruxtecan FDA

     Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.

     Broad match: EGFR mutation (unspecified)Stomatitis

199. Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

     Not yet recruiting Phase 3 PrECOG Starts 2027Primary completion 2037-11 NCT07637513

     Tarlatamabdurvalumab

     …previous diagnosis of non-small cell lung cancer (e.g., Epidermal Growth Factor Receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with SCLC transformation).

     Broad match: EGFR mutation (unspecified)Limited Stage Small-Cell Lung Cancer

200. A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)

     Recruiting Phase 3 Baili-Bio / SystImmune Started 2026Primary completion 2030-12 NCT07640789

     izalontamab brengitecanosimertinib FDA EU

     …With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definiti…

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer Stage III

201. A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

     Recruiting Phase 2/3 Baili-Bio / SystImmune Started 2026Primary completion 2032-12 NCT07642024

     izalontamab brengitecanosimertinib FDA EUcarboplatinpemetrexedcisplatin

     …udy of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

202. Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

     Not yet recruiting Phase 2/3 Sir Run Run Shaw Hospital Started 2026Primary completion 2027-12 NCT07598318

     Becotatug VedotinPucotenlimabgemcitabinecisplatin

     Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

     Broad match: EGFR mutation (unspecified)Cholangiocarcinoma

203. SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

     Not yet recruiting Phase 3 CSPC Started 2026Primary completion 2027-12 NCT07442565

     SYS6010docetaxel

     EGFR mutations (currently approved by regulatory authorities for targeted therapy) must be confirmed neg…

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

204. ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

     Recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2025Primary completion 2027-10 NCT07109531

     limertinibpemetrexedcisplatincarboplatin

     EGFR mutation with MET amplification/Overexpression by a central laboratory;

     Broad match: EGFR mutation (unspecified)Locally Advanced or Metastatic NSCLC

205. Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

     Recruiting Phase 3 CSPC Started 2025Primary completion 2026-07 NCT06927986

     SYS6010pemetrexedcisplatincarboplatin

     Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

     Broad match: EGFR mutation (unspecified)EGFR-mutated Locally Advanced or Metastatic NSCLC

206. A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

     Recruiting Phase 3 Baili-Bio / SystImmune Started 2025Primary completion 2028-12 NCT06838273

     izalontamab brengitecanosimertinib FDA EU

     …sue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

207. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

     Recruiting Phase 3 Pfizer Started 2025Primary completion 2028-03 NCT07144280

     PF-08046054docetaxel

     Participants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following c…

     Broad match: EGFR mutation (unspecified)Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

208. A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

     Recruiting Phase 3 Taiho Pharmaceutical Started 2025Primary completion 2029-10 NCT07128199

     zipalertinib

     …Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

     Broad match: EGFR sensitizing mutationLung Cancer, Adjuvant, Post-surgical, EGFR

209. Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

     Not yet recruiting Phase 2/3 Shanghai JMT-Bio Started 2025Primary completion 2028-12 NCT06908772

     glumetinibosimertinib FDA EU

     …ined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

     Broad match: EGFR sensitizing mutationRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

210. Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

     Not yet recruiting Phase 3 Avistone Biotechnology Started 2025Primary completion 2027-12 NCT06970782

     vebreltinibPLB1004pemetrexedcarboplatincisplatin

     Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

     Broad match: EGFR mutation (unspecified)Non-Small-Cell Lung Cancer

211. A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

     Active, not recruiting Phase 3 Jiangsu Hengrui Started 2025Primary completion 2032-11 NCT07183189

     SHR-A2009aumolertinib

     …lly confirmed locally advanced, metastatic, or recurrent non-small cell lung cancer, with EGFR mutations confirmed by tissue or blood specimens.

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

212. A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

     Active, not recruiting Phase 3 Kelun-Biotech Started 2024Primary completion 2027-05 NCT06670196

     sacituzumab tirumotecanosimertinib FDA EU

     …on With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

213. A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

     Active, not recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2026-12 NCT06671379

     SHR-A2009platinum-based dual-agent chemotherapy

     A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

214. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

     Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2024Primary completion 2028-08 NCT06305754

     sacituzumab tirumotecanpemetrexedcarboplatinH1 Receptor AntagonistH2 Receptor AntagonistAcetaminophen (or equivalent)dexamethasone

     …etrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGF…

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

215. A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

     Active, not recruiting Phase 3 Baili-Bio / SystImmune Started 2024Primary completion 2026-08 NCT06382116

     izalontamab brengitecanpemetrexedcisplatincarboplatin

     Documented classical EGFR mutations detected from tumor tissue or blood samples;

     Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

216. Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

     Recruiting Phase 3 Qianfoshan Hospital Started 2023Primary completion 2026-09 NCT06043973

     aumolertinibanlotinib

     Patients with EGFR mutation and TP53 mutation advanced Non-squamous NSCLC.

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2023-09-21Advanced Non-small Cell Lung Cancer

217. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

     Active, not recruiting Phase 3 MSD (Merck & Co.) Started 2023Primary completion 2027-05 NCT06074588

     sacituzumab tirumotecandocetaxelpemetrexed

     …iously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

218. A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

     Active, not recruiting Phase 3 Kelun-Biotech Started 2023Primary completion 2024-07 NCT05870319

     sacituzumab tirumotecanpemetrexedcarboplatincisplatin

     A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

219. REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

     Active, not recruiting Phase 3 Taiho Pharmaceutical Started 2023Primary completion 2027-05 NCT05973773

     zipalertinib

     Part A: EGFR ex20ins or other uncommon single or compound EGFR mutation

     Broad match: EGFR mutation (unspecified)Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

220. Phase 3 Clinical Study of AK112 for NSCLC Patients

     Active, not recruiting Phase 3 Akeso Started 2022Primary completion 2023-03 NCT05184712

     ivonescimabpemetrexedcarboplatin

     The tumor histology, cytology or hematology confirmed the presence of EGFR activating mutations before enrollment

     Broad match: EGFR sensitizing mutationNon-Squamous Non-small Cell Lung Cancer

221. Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

     Recruiting Phase 3 TYK Medicines Started 2022Primary completion 2025-05 NCT05382728

     TY-9591osimertinib FDA EU

     Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

     Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-01-30NSCLC, EGFR Activating Mutation

222. EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

     Recruiting Phase 3 Region Skane Started 2022Primary completion 2028-09 NCT06486142

     afatinib FDA EUdacomitinib FDA EUosimertinib FDA EU

     EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating…

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

223. Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

     Recruiting Phase 3 Instituto Nacional de Cancerologia de Mexico Started 2021Primary completion 2026-07 NCT05445791

     metformin

     Patients with non-small cell lung cancer and a documented EGFR sensitizing mutation.

     Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

224. FHND9041 Versus Afatinib for Non-small Cell Lung Cancer

     Enrolling by invitation Phase 3 Chia Tai Tianqing (Sino Biopharm) Started 2021Primary completion 2025-03 NCT06759857

     FHND9041afatinib FDA EU

     …nce of a confirmed EGFR-positive gene mutation sensitive to EGFR-TKI treatment, including exon 19 deletion or L858R mutation.

     Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

225. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

     Active, not recruiting Phase 3 Johnson & Johnson Started 2020Primary completion 2023-08 NCT04487080

     amivantamab FDA EUosimertinib FDA EUlazertinib FDA EU

     The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administrati…

     Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung

226. PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

     Active, not recruiting Phase 3 UNICANCER Started 2018Primary completion 2026-12 NCT03774732

     pembrolizumabcarboplatinpaclitaxelnab-paclitaxelcisplatinpemetrexed

     Non-squamous NSCLC with targetable tumor mutations, activating EGFR mutations or ALK translocation Note: documentation of these mutation for non-squamous histology is …

     Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4

227. Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

     Not yet recruiting Phase 2 Jonsson Comprehensive Cancer Center Starts 2027Primary completion 2029-06 NCT07229339

     carboplatinpemetrexedzipalertinib

     …llment with EGFR Ex20Ins-mutated (addition of 1 or more amino acids) or uncommon/compound EGFR mutations (E709X, G719X, L747X, S758I, and/or L861Q) in tumor tissue or blood

     Broad match: EGFR mutation (unspecified)Lung Non-Squamous Non-Small Cell Carcinoma

228. Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

     Recruiting Phase 1/2 Misty Shields Starts 2027Primary completion 2029-04 NCT07153055

     Lurbinectedinosimertinib FDA EU

     Must have an initial diagnosis of EGFR altered (EGFR-mutated) non-small cell lung cancer and received EGFR targeted therapy (TKI) osimer…

     Broad match: EGFR mutation (unspecified)Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer

229. A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

     Not yet recruiting Phase 2 Anhui Provincial Cancer Hospital Started 2026Primary completion 2029-03 NCT07661173

     furmonertinibpemetrexedcarboplatinbevacizumab

     Confirmed presence of EGFR mutation-positive by tumor histology, cytology, or hematology;

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

230. Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

     Recruiting Phase 2 Kelun-Biotech Started 2026Primary completion 2027-08 NCT07329322

     sacituzumab tirumotecanosimertinib FDA EU

     Confirmed by tumor histology, or cytology to have EGFR sensitizing mutations.

     Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

231. Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

     Not yet recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2026Primary completion 2026-05 NCT07365410

     furmonertinibcarboplatinpemetrexed

     Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation

232. Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

     Not yet recruiting Phase 1/2 National University Hospital, Singapore Started 2026Primary completion 2028-08 NCT07681297

     tislelizumabbevacizumabcapecitabine

     Patients with driver mutations (e.g., EGFR-mutant or ALK-rearranged NSCLC, HER2+ metastatic breast cancer) must have received at least one …

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer

233. A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

     Recruiting Phase 1/2 Avistone Biotechnology Started 2026Primary completion 2029-06 NCT07538804

     ANS02

     With documentation of EGFR alteration

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

234. AMT-116 in Combination With AK112 in Patients With Lung Cancer

     Recruiting Phase 1/2 Multitude Therapeutics Started 2026Primary completion 2027-05 NCT07590531

     AMT-116ivonescimab

     …ort 3: Histologically or cytologically diagnosed with non-squamous NSCLC and harboring an EGFR mutation.

     Broad match: EGFR mutation (unspecified)Advanced Non-small Cell Lung Cancer (NSCLC)

235. Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

     Recruiting Phase 2 Black Diamond Therapeutics Started 2026Primary completion 2028-11 NCT07326566

     silevertinibtemozolomide

     For Part 1 (Safety Lead-in) ONLY: EGFR alterations.

     Broad match: EGFR mutation (unspecified)Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)

236. BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

     Not yet recruiting Phase 1/2 Xcovery Holdings Started 2026Primary completion 2028-01 NCT05393466

     BPI-361175

     …lly confirmed diagnosis of inoperable locally advanced or recurrent/metastatic NSCLC with EGFR mutations.

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Carcinoma

237. Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

     Not yet recruiting Phase 2 Xiaorong Dong Started 2026Primary completion 2027-07 NCT07789444

     sacituzumab tirumotecan

     Presence of EGFR-sensitizing mutations, including exon 19 deletion or exon 21 L858R point mutation.

     Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

238. Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases

     Not yet recruiting Phase 2 Bing Xia Started 2026Primary completion 2029-04 NCT07875465

     PD-1/PD-L1 inhibitorsCombined Chemotherapy

     Cohort B: Advanced NSCLC with positive driver genes (EGFR/ALK/ROS1), disease progression during first-line targeted therapy.

     Broad match: EGFR mutation (unspecified)Liver Metastases, Non-Small Cell Lung Cancer, Colorectal Cancer (Diagnosis), Pancreatic Cancer Metastatic

239. Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma

     Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2026Primary completion 2028-05 NCT07744529

     amivantamab FDA EUpemetrexed

     Patients with EGFR-mutated lung adenocarcinoma with leptomeningeal metastasis diagnosed according to the EANO-ESMO g…

     Broad match: EGFR mutation (unspecified)Leptomeningeal Metastasis From Lung Cancer

240. A Phase 2 Study of ABSK043 Combined With Osimertinib

     Not yet recruiting Phase 2 Abbisko Therapeutics Started 2026Primary completion 2029-12 NCT07710612

     osimertinib FDA EU

     Documented genetic testing report confirms the presence of EGFR alteration(s) in tumor or plasma.

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive

241. Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

     Recruiting Phase 2 Pfizer Started 2026Primary completion 2028-03 NCT07476287

     PF-08634404Chemotherapy

     Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).

     Broad match: EGFR mutation (unspecified)Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms

242. Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

     Recruiting Phase 2 Mayo Clinic Started 2026Primary completion 2036-08 NCT07708961

     WSD0922temozolomide

     Glioblastomas must have a pathogenic EGFR mutation, with or without EGFR amplification, detected by Clinical Laboratory Improvement Act (CLI…

     Broad match: EGFR mutation (unspecified)Glioblastoma, IDH-Wildtype

243. A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

     Not yet recruiting Phase 1/2 Beijing Pearl Biotechnology Started 2026Primary completion 2029-12 NCT07285148

     PLB1004osimertinib FDA EU

     Have a documented EGFR positive mutation (EGFR classic mutations including ex19del and ex21 L858R, uncommon mutations and ex20 insertion mutations) in tumor tissue samples …

     Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration

244. Boosting Osimertinib Blood Brain Barrier Penetration

     Recruiting Phase 2 Maastricht University Medical Center Started 2026Primary completion 2027-06 NCT07485452

     osimertinib FDA EU

     The patient has metastatic EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable di…

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

245. First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations

     Not yet recruiting Phase 2 Yongsheng Wang Started 2026Primary completion 2029-03 NCT07699952

     aumolertinibtrastuzumab rezetecan

     Confirmed EGFR mutations via genetic testing, including Exon 19 deletion or L858R point mutation;

     Broad match: EGFR exon 19 deletionLung Cancer (NSCLC), EGFR Activating Mutation, HER2

246. Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

     Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2026Primary completion 2026-06 NCT07323056

     sacituzumab tirumotecanlimertinib

     Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology

     Broad match: EGFR mutation (unspecified)EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable

247. A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

     Recruiting Phase 1/2 Memorial Sloan Kettering Cancer Center Started 2026Primary completion 2028-04 NCT07535437

     ivonescimabdatopotamab deruxtecan FDAosimertinib FDA EU

     A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

248. The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

     Not yet recruiting Phase 2 Fudan University Started 2026Primary completion 2028-09 NCT07780578

     Andamertinibanlotinib

     Harboring EGFR mutations (including exon19 deletions and exon21 L858R mutation), with documented disease progressed following only one prior …

     Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

249. A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

     Not yet recruiting Phase 2 Kelun-Biotech Started 2026Primary completion 2027-12 NCT07854509

     sacituzumab tirumotecan

     Confirmed EGFR-sensitizing mutations.

     Broad match: EGFR sensitizing mutationNon-Squamous Non-Small Cell Lung Cancer

250. Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

     Recruiting Phase 2 Avistone Biotechnology Started 2026Primary completion 2026-11 NCT07336732

     PLB1004

     …ublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

     Broad match: EGFR sensitizing mutationNon-Small-Cell Lung Cancer

251. Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

     Not yet recruiting Phase 2 Hubei Cancer Hospital Started 2026Primary completion 2028-03 NCT07807722

     furmonertinibanlotinib

     EGFR mutation positive non-small cell lung cancer (including 19Del and 21L858R) confirmed by biopsy

     Broad match: EGFR exon 19 deletionNSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy

252. A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy

     Not yet recruiting Phase 1/2 Shanghai Best-Link Bioscience Started 2026Primary completion 2027-12 NCT07414927

     BL0020

     Patients with initial diagnosis of EGFR-mutated NSCLC and histologically or cytologically confirmed transformation to SCLC following trea…

     Broad match: EGFR mutation (unspecified)Small Cell Carcinoma of Lung

253. Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors

     Not yet recruiting Phase 1/2 Regeneron Started 2026Primary completion 2031-03 NCT07863024

     REGN13089-M404-M2980

     Histologically confirmed cancer (non-small cell lung cancer (epidermal growth factor receptor mutant type or epidermal growth factor receptor mutant type), colorectal cancer, gastric/gastroe…

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

254. DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

     Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025Primary completion 2027-06 NCT07070440

     DZD6008pemetrexedcarboplatindocetaxel

     Documentation of EGFR sensitizing mutation confirmed by local laboratory.

     Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer

255. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

     Recruiting Phase 1/2 Hummingbird Bioscience Started 2025Primary completion 2027-07 NCT06956690

     ENV-501

     Locally advanced or metastatic mutated EGFR (mEGFR) NSCLC (HER3+)

     Broad match: EGFR mutation (unspecified)Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer

256. Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

     Recruiting Phase 2 University Hospital, Bonn Started 2025Primary completion 2029-12 NCT06810609

     Immunotherapy

     Histologically and / or cytologically proven NSCLC (EGFRm-, ALK-). 8.

     Broad match: EGFR mutation (unspecified)Lung Cancer Non-Small Cell Cancer (NSCLC)

257. Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

     Not yet recruiting Phase 2 Zhejiang Cancer Hospital Started 2025Primary completion 2028-05 NCT06861218

     pemetrexedvometinib

     Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations.

     Broad match: EGFR mutation (unspecified)Leptomeningeal Metastases

258. Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

     Recruiting Phase 2 The First Affiliated Hospital of Xiamen University Started 2025Primary completion 2026-05 NCT06929936

     docetaxel

     Definition of driver genes: EGFR (including 19del, L858R, S768I, L861Q, and/or G719X), BRAF V600E, NTRK, MET14 exon skipping mutation, RET,…

     Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, Myelosuppression

259. A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

     Recruiting Phase 1/2 MediLink Therapeutics Started 2025Primary completion 2027-01 NCT07208773

     YL201ivonescimab

     Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation NSCLC.

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer

260. A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

     Not yet recruiting Phase 2 CSPC Started 2025Primary completion 2026-11 NCT07256509

     SYS6010osimertinib FDA EUpemetrexedcisplatincarboplatin

     …mbined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

261. Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer

     Not yet recruiting Phase 2 Jianxing He Started 2025Primary completion 2028-10 NCT07177092

     osimertinib FDA EU

     Presence of EGFR exon 19 deletion (19Del) or L858R mutation, confirmed by ARMS-PCR, NGS, or other validated methods.

     Broad match: EGFR exon 19 deletionNon-Small Cell Lung Cancer, EGFR

262. Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

     Not yet recruiting Phase 1/2 Avistone Biotechnology Started 2025Primary completion 2028-03 NCT07063329

     PLB1004

     Patients with other EGFR mutations such as EGFR exon 20 insertion: They must have received platinum-based chemotherapy.

     Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer)

263. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

     Recruiting Phase 1/2 BlossomHill Therapeutics Started 2025Primary completion 2029-01 NCT06706076

     BH-30643carboplatinpemetrexed

     Pathologically confirmed diagnosis of locally advanced or metastatic NSCLC with EGFR or HER2 mutations in the kinase domain of exons 18, 19, 20, or 21.

     Broad match: EGFR mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer)

264. A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

     Recruiting Phase 1/2 Henan Genuine Biotech Started 2025Primary completion 2027-07 NCT07362940

     GEN-725 tablets + Dositinib mesylate tablets

     Patients with a positive EGFR mutation. (For patients with prior third-generation EGFR-TKI therapy, post-progression EGFR mutati…

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

265. CVL006 Combination Therapy in Advanced Solid Tumors

     Not yet recruiting Phase 1/2 Convalife Started 2025Primary completion 2028-08 NCT07157956

     pemetrexedcarboplatinsacituzumab tirumotecantrastuzumab deruxtecanenfortumab vedotin

     …rm2.1, Arm2.2, Arm2.5 and Arm2.7: For NSCLC Arm2.1: Non-squamous, wild-type NSCLC Arm2.2: EGFRm nsqNSCLC Arm2.3: Malignant pleural mesothelioma Arm2.4: triple-negative breast cancer Arm…

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

266. Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

     Recruiting Phase 2 Qingdao Central Hospital Started 2025Primary completion 2026-12 NCT07322783

     savolitinibosimertinib FDA EU

     Osimertinib Combined With Savolitinib in the Treatment of EGFR Mutated Osimertinib Resistant NSCLC With Low Copy Number MET Amplification

     Broad match: EGFR mutation (unspecified)EGFR Positive Non-small Cell Lung Cancer, MET Amplification

267. Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

     Recruiting Phase 2 The First Affiliated Hospital of Xiamen University Started 2025Primary completion 2027-03 NCT06992739

     sacituzumab tirumotecan

     Patients with locally advanced or metastatic EGFR mutant non-small cell lung cancer diagnosed by histological or cytological examination, who have…

     Broad match: EGFR mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression

268. Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

     Recruiting Phase 2 Peng Zhang Started 2025Primary completion 2027-11 NCT07742332

     Fumetinib combined platinum-based double chemotherapyConcurrent Radiochemotherapy

     Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

     Broad match: EGFR mutation (unspecified)EGFR, NSCLC (Non-small Cell Lung Cancer), Locally Advanced Non-Small Cell Lung Cancer, Radiotherapy

269. A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

     Not yet recruiting Phase 2 TYK Medicines Started 2025Primary completion 2027-12 NCT06672068

     TY-9591pemetrexedcisplatincarboplatin

     Tissue or blood samples tested positive for EGFR sensitive mutations (including exon 19 deletion, exon 21 L858R mutation, alone or in combination with other EGFR mutations) by central la…

     Broad match: EGFR exon 19 deletionNSCLC

270. A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

     Not yet recruiting Phase 2 Wen-zhao ZHONG Started 2025Primary completion 2027-12 NCT07038460

     limertinibsintilimabosimertinib FDA EU

     …ollowed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

     Broad match: EGFR mutation (unspecified)Resectable Non-small Cell Lung Cancer

271. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

     Active, not recruiting Phase 1/2 Merck KGaA Started 2025Primary completion 2027-12 NCT06710132

     M9140

     …essing EGFR tumors (including participants with any driver genomic alterations other than EGFR mutations

     Broad match: EGFR mutation (unspecified)Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

272. High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

     Not yet recruiting Phase 2 Peking University Cancer Hospital & Institute Started 2025Primary completion 2029-12 NCT07182708

     furmonertinibbevacizumab

     EGFR mutation-positive confirmed by local laboratory testing of tissue or blood samples.

     Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma

273. Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

     Recruiting Phase 2 The Netherlands Cancer Institute Started 2025Primary completion 2027-05 NCT06222489

     patritumab deruxtecan

     Have a histologically or cytologically confirmed diagnosis of (locally) advanced stage EGFR mutation positive NSCLC, not amenable for curative intent treatment.

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation

274. A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

     Recruiting Phase 2 Wayshine Biopharm Started 2025Primary completion 2027-09 NCT06868485

     WSD0922

     Documented EGFR mutation .

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

275. A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

     Recruiting Phase 1/2 Henlius Started 2025Primary completion 2026-10 NCT06848699

     HLX43serplulimab

     … /metastatic NSCLC subjects confirmed by histology or cytology, requiring the presence of EGFR mutation and failure or intolerance to EGFR-TKI or/and platinum-based chemotherapy.

     Broad match: EGFR mutation (unspecified)Solid Tumor Cancer, Non Small Cell Lung Cancer

276. A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

     Recruiting Phase 1/2 Suzhou Genhouse Bio Started 2024Primary completion 2025-12 NCT06306456

     GH21osimertinib FDA EU

     Advanced NSCLC patients with EGFR mutations confirmed by cytological or histological assessments, and meet the following requirement:

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-07-08Non-Small Cell Lung Cancer With EGFR Mutation

277. High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

     Recruiting Phase 2 Jialei Wang Started 2024Primary completion 2026-12 NCT06652048

     furmonertinib

     High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

278. Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

     Recruiting Phase 2 BeBetter Med Started 2024Primary completion 2027-06 NCT06514027

     BEBT-109 Capsulespemetrexedcarboplatincisplatin

     Patients may have only EGFR exon 20 insertion mutations or may also have other EGFR or HER2 mutations;

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

279. A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

     Not yet recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2024Primary completion 2025-11 NCT06585644

     furmonertinib

     Inclusion Criteria: 1) EGFR mutation-positive (including 19Del and 21L858R) non-small cell lung cancer (NSCLC) confirmed by biopsy

     Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-09-05Lung Cancer (NSCLC)

280. Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

     Recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2024Primary completion 2025-10 NCT06383728

     osimertinib FDA EU

     Gene text confirmed EGFR mutation;

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-05-09Lung Cancer, Carcinoma, Squamous Cell

281. A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

     Recruiting Phase 2 Johnson & Johnson Started 2024Primary completion 2029-05 NCT06667076

     amivantamab FDA EUlazertinib FDA EUpemetrexedcarboplatin

     …Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

     Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung

282. Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

     Active, not recruiting Phase 2 Johnson & Johnson Started 2024Primary completion 2027-05 NCT06120140

     amivantamab FDA EUlazertinib FDA EUDoxycyclineMinocyclineClindamycinChlorhexidineZinc gluconatePropranololTimololClobetasol

     Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-appro…

     Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung

283. Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

     Recruiting Phase 2 Ruijin Hospital Started 2024Primary completion 2027-01 NCT06269211

     toripalimab

     Confirmation by the central laboratory that the tumor harbors EGFR mutations either sensitive mutations, uncommon mutations or complex mutations.

     Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

284. Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

     Enrolling by invitation Phase 2 Yonsei University Started 2024Primary completion 2026-12 NCT06250777

     trastuzumab deruxtecan

     Activating HER2-mutation documented by NGS in tissue or plasma (include activating HER2 mutation in exon 19 or 20, i.e. , Exon 20: A775\_G776insYVMA insertion/duplication

     Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

285. A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

     Recruiting Phase 1/2 Yuhan Started 2024Primary completion 2028-03 NCT06616766

     YH42946

     …ssue in quantity sufficient to allow for retrospective confirmation of HER2 aberration or EGFR mutation

     Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer), Solid Tumor

286. A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

     Not yet recruiting Phase 2 Shanghai Zhongshan Hospital Started 2024Primary completion 2026-01 NCT06182761

     sunvozertinibanlotinib

     EGFR sensitive mutations confirmed by accredited local laboratories， including 19del、L858R and T790M。

     Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2023-12-27NSCLC

287. A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor

     Recruiting Phase 1/2 Huabo Biopharm Started 2024Primary completion 2025-10 NCT06758557

     HB0025pemetrexedpaclitaxelcarboplatin

     3.1.3 Patients with tyrosine kinase inhibitor (TKI) drug sensitivity mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) translocation, who have experienced disease progres…

     Broad match: EGFR mutation (unspecified)Advanced NSCLC, Advanced Endometrial Cancer

288. Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

     Recruiting Phase 2 Taipei Veterans General Hospital, Taiwan Started 2024Primary completion 2026-12 NCT05805631

     pemetrexed

     Patients with metastatic non-squamous NSCLC harboring known EGFR activating mutation and with a diagnosis of probable or confirmed LM by the European Association of Neuro-Onc…

     Broad match: EGFR sensitizing mutationCarcinoma, Non-Small-Cell Lung, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis

289. Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

     Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2024Primary completion 2025-12 NCT06483672

     furmonertinibanlotinib

     Tumor tissue samples or blood samples are confirmed to be EGFR mutations;

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-07-03Adenocarcinoma of Lung Metastatic to Brain

290. Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

     Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2026-12 NCT06440954

     pemetrexed

     EGFR mutant, ALK fusion, ROS1 fusion, and other oncogenic alterations including RET fusion, BRAF muta…

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-06-04Non-Small Cell Lung Cancer

291. Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

     Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2025-10 NCT06348927

     sunvozertinibanlotinib

     EGFR-sensitive mutations confirmed by an accredited local laboratory, including exon 19 deletions, exon 21 L858R point mutations, and T790M mutations, combined with co-mutations, includi…

     Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer

292. Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

     Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine Started 2024Primary completion 2027-06 NCT06863506

     befotertinib

     Documented EGFR mutations: Cohort 1 (G719X/L861Q/S768I) or Cohort 2 (exon 20 insertion)

     Broad match: EGFR mutation (unspecified)NSCLC (Non-small Cell Lung Cancer)

293. A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

     Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2024Primary completion 2027-12 NCT06741085

     osimertinib FDA EU

     Non-small cell lung cancer (NSCLC) with somatic activating mutation in EGFR diagnosis, confirmed at enrolling institution

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer Metastatic

294. Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

     Recruiting Phase 2 Hunan Province Tumor Hospital Started 2024Primary completion 2025-12 NCT06355609

     sunvozertinibanlotinib

     EGFR-sensitive mutations confirmed by an accredited local laboratory, including exon 19 deletions, exon 21 L858R point mutations, and T790M mutations, combined with co-mutations, includi…

     Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-09-20Non-small Cell Lung Cancer

295. Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

     Recruiting Phase 2 Peng Zhang Started 2024Primary completion 2025-12 NCT06755684

     befotertinibbevacizumab

     …ombined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

     Broad match: EGFR mutation (unspecified)EGFR, Non-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Pemetrexed

296. A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

     Recruiting Phase 1/2 AstraZeneca Started 2024Primary completion 2028-12 NCT06130553

     AZD3470datopotamab deruxtecan FDA

     …defined criteria) and the participant has received prior systemic therapy appropriate for EGFR-altered advanced/metastatic NSCLC (per protocol), OR Tumor is negative for EGFR alterations eligi…

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumors That Are MTAP Deficient

297. A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

     Recruiting Phase 1/2 Wayshine Biopharm Started 2024Primary completion 2027-06 NCT06631989

     WSD0922

     A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

     Broad match: EGFR mutation (unspecified)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

298. Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

     Recruiting Phase 1/2 China Medical University Hospital Started 2024Primary completion 2026-08 NCT06071013

     gefitinib FDA EUerlotinib FDA EUafatinib FDA EUosimertinib FDA EU

     Positive EGFR mutations are diagenesis.

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation

299. Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

     Recruiting Phase 1/2 Sichuan University Started 2024Primary completion 2027-12 NCT06195189

     sunvozertinibChemotherapy

     EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.

     Broad match: EGFR exon 19 deletionNon Small Cell Lung Cancer

300. Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

     Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital Started 2024Primary completion 2025-12 NCT06363734

     osimertinib FDA EU

     Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistan…

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-04-16Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation

301. High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

     Not yet recruiting Phase 2 Taizhou Hospital Started 2024Primary completion 2026-12 NCT06319950

     furmonertinibosimertinib FDA EU

     The tissue or blood sample is determined to be EGFR positive (including rare EGFR mutations) by testing by a tertiary Class A hospital or a qualified testing institution, and the ti…

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-03-20Lung Cancer, Nonsmall Cell

302. Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

     Recruiting Phase 2 Sun Yat-sen University Started 2024Primary completion 2026-07 NCT06517953

     icotinibbefotertinib

     Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

     Broad match: EGFR sensitizing mutationStatus may be outdated, last updated 2024-07-25Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I

303. A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

     Recruiting Phase 1/2 J Ints Bio Started 2023Primary completion 2026-09 NCT05394831

     JIN-A02

     …thologically confirmed and finally diagnosed advanced and/or metastatic NSCLC with active EGFR mutant

     Broad match: EGFR mutation (unspecified)EGFR Mutant Advanced Non-small Cell Lung Cancer

304. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

     Recruiting Phase 2 Teligene Started 2023Primary completion 2027-12 NCT06010329

     Sutetinib Maleate Capsule

     …ficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

     Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

305. A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

     Recruiting Phase 1/2 D3 Bio Started 2023Primary completion 2028-08 NCT05886920

     D3S-002D3S-001

     Note: EGFR mutations include but are not limited to EGFR Exon19 Deletions, Exon21 p.L858R, Exon21 p.L861Q, Exon18 p.G719X, Exon20 p.S768I, Exon20 Insertions, Exon20 p.T790M.

     Broad match: EGFR L858RAdvanced Solid Tumors With MAPK Pathway Mutations

306. Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

     Recruiting Phase 2 CrystalGenomics Started 2023Primary completion 2026-08 NCT05841472

     camrelizumabpemetrexedcarboplatin

     Subject cannot be randomized before receiving the source document for EGFR mutation and ALK translocation.

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2023-08-30Non Squamous Non Small Cell Lung Cancer

307. Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

     Recruiting Phase 1/2 Avistone Biotechnology Started 2023Primary completion 2026-12 NCT06343064

     vebreltinibPLB1004

     EGFR mutations, including exon 19 deletion and exon 21 L858R.

     Broad match: EGFR exon 19 deletionNon-Small-Cell Lung Cancer

308. A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

     Active, not recruiting Phase 2 AstraZeneca Started 2023Primary completion 2027-10 NCT05801029

     osimertinib FDA EUamivantamab FDA EU

     …icacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

     Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer (NSCLC)

309. A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

     Active, not recruiting Phase 2 National Cancer Centre, Singapore Started 2023Primary completion 2025-10 NCT05773092

     osimertinib FDA EU

     Patients must have histologically or cytologically confirmed EGFR mutant NSCLC.

     Broad match: EGFR mutation (unspecified)NSCLC

310. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

     Active, not recruiting Phase 2 Klus Pharma Started 2023Primary completion 2026-06 NCT05816252

     sacituzumab tirumotecanpembrolizumabcarboplatinosimertinib FDA EU

     or confirmed to harbor EGFR mutation;

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer

311. The Efficacy and Safety of IBI363 in Solid Tumors

     Recruiting Phase 1/2 Hunan Province Tumor Hospital Started 2023Primary completion 2026-12 NCT06081907

     IBI363lenvatinib

     …F: Patients with histological or cytological confirmation of advanced NSCLC who harboring EGFR mutation and failed standard treatment.

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-05-30Advanced Solid Tumor

312. IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

     Recruiting Phase 1/2 InxMed Started 2023Primary completion 2026-07 NCT05994131

     ifebemtinibfurmonertinib

     Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R.

     Broad match: EGFR exon 19 deletionNSCLC

313. Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

     Active, not recruiting Phase 2 ETOP IBCSG Partners Foundation Started 2023Primary completion 2024-08 NCT05601973

     amivantamab FDA EUlazertinib FDA EUZirabev

     Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TK…

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

314. Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

     Active, not recruiting Phase 2 Guangdong Association of Clinical Trials Started 2023Primary completion 2026-07 NCT05957510

     serplulimabetoposidecarboplatinSOC

     …on, and the reports clearly indicate that they were non-small cell lung cancer containing EGFR mutations before transformation.

     Broad match: EGFR mutation (unspecified)Small-cell Lung Cancer

315. Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

     Recruiting Phase 2 SWOG Cancer Research Network Started 2023Primary completion 2027-06 NCT05642572

     capmatinibosimertinib FDA EUramucirumab FDA EU

     Participants must have documentation of NSCLC with a sensitizing EGFR mutation and have radiologically or clinically progressed (in the opinion of the treating physicia…

     Broad match: EGFR sensitizing mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8

316. TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

     Recruiting Phase 2 TYK Medicines Started 2023Primary completion 2025-12 NCT05948813

     TY-9591osimertinib FDA EU

     Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites)…

     Broad match: EGFR exon 19 deletionNSCLC, EGFR Activating Mutation, Brain Metastases

317. To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

     Recruiting Phase 2 Abion Started 2023Primary completion 2029-02 NCT05541822

     Vabametkiblazertinib FDA EU

     EGFR mutation-positive including exon 19 deletions or exon 21 L858R as detected by an FDA-approved or other validated test in a CLIA certif…

     Broad match: EGFR exon 19 deletionAdvanced Solid Tumors

318. Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

     Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2022Primary completion 2023-10 NCT05503667

     furmonertinibbevacizumab

     …umab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2022-08-17Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation

319. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

     Recruiting Phase 2 Teligene Started 2022Primary completion 2027-12 NCT05168566

     Sutetinib Maleate Capsule

     Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excludi…

     Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

320. Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

     Active, not recruiting Phase 1/2 Washington University School of Medicine Started 2022Primary completion 2027-01 NCT04743505

     vebreltinibosimertinib FDA EU

     …ncer, or locally advanced disease that is not amendable for curative intent therapy, with TKI-sensitive EGFR mutation through CLIA certified lab.

     Broad match: EGFR sensitizing mutationMetastatic Non Small Cell Lung Cancer

321. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

     Recruiting Phase 1/2 ORIC Pharmaceuticals Started 2022Primary completion 2026-09 NCT05315700

     ORIC-114carboplatinpemetrexed

     …d or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/…

     Broad match: EGFR sensitizing mutationSolid Tumors

322. Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

     Not yet recruiting Phase 1/2 Jiangsu Hengrui Started 2022Primary completion 2027-07 NCT05503888

     aumolertinib

     …Innovative Drugs in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer With EGFR Mutation

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2022-08-17Relapsed or Advanced Non-small Cell Lung Cancer

323. SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

     Recruiting Phase 2 Kelun-Biotech Started 2022Primary completion 2026-08 NCT05351788

     sacituzumab tirumotecanKL-A167carboplatincisplatin

     Cohort 3: Patients with locally advanced/metastatic NSCLC with EGFR activating mutation and negative ALK fusion gene, who have failed previous treatment with EGFR-TKIs.

     Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

324. Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

     Active, not recruiting Phase 2 Li Zhang, MD Started 2022Primary completion 2025-11 NCT05003037

     surufatinibtoripalimabpemetrexedcarboplatincisplatin

     EGFR mutation cases are not expected to exceed 50% of all enrolled patients in Cohort 2.

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer

325. Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

     Active, not recruiting Phase 2 AIO-Studien-gGmbH Started 2022Primary completion 2026-03 NCT05089916

     osimertinib FDA EU

     …ding to marketing authorization (first line treatment of tumor positive for a common or uncommon EGFR mutation, or later line treatment of tumor positive for EGFR T790M mutation, assessed according to…

     Broad match: EGFR sensitizing mutationNSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression

326. Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

     Active, not recruiting Phase 1/2 Black Diamond Therapeutics Started 2022Primary completion 2025-11 NCT05256290

     silevertinib

     …ed resistance C797S cohort): Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only one EGFR TKI, which must be a third ge…

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer

327. A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation

     Recruiting Phase 1/2 Henan Genuine Biotech Started 2022Primary completion 2027-12 NCT07231068

     Dositinib mesylate tablets

     Patients with confirmed EGFR activating mutations that are sensitive to EGFR TKI at any time after initial diagnosis, in dose escalation p…

     Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer

328. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

     Recruiting Phase 1/2 Genmab Started 2022Primary completion 2027-07 NCT05579366

     rinatabart sesutecancarboplatinbevacizumabpembrolizumaberythromycinitraconazole

     …ncer, or fallopian tube cancer), endometrial cancer, non-small cell lung cancer (Part A), EGFR-mutated NSCLC (Part B), breast cancer (hormone receptor positive, HER2-negative and triple-negati…

     Broad match: EGFR mutation (unspecified)High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

329. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

     Recruiting Phase 1/2 Betta Pharmaceuticals Started 2021Primary completion 2028-04 NCT04930432

     MCLA-129

     For patients with advanced NSCLC, EGFR positive is defined as: EGFR mutation or EGFR amplification.

     Broad match: EGFR mutation (unspecified)Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer

330. Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

     Active, not recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2021Primary completion 2022-12 NCT04685070

     aumolertinib

     Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-08-14Non-small Cell Lung Cancer Stage III

331. JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

     Active, not recruiting Phase 2 Shanghai JMT-Bio Started 2021Primary completion 2023-05 NCT06391944

     JMT101osimertinib FDA EU

     … to the 8th edition of the AJCC TNM staging criteria) or metastatic (Stage IV) harbouring EGFR common mutation with tumour tissue/blood sample.

     Broad match: EGFR sensitizing mutationStatus may be outdated, last updated 2024-04-30Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation

332. Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

     Recruiting Phase 1/2 Emory University Started 2021Primary completion 2025-08 NCT04590664

     Verteporfin

     …hase 1 / 2 Study of Visudyne (Liposomal Verteporfin) in Persons with Recurrent High Grade EGFR-Mutated Glioblastoma

     Broad match: EGFR mutation (unspecified)Glioblastoma, Recurrent Glioblastoma

333. Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

     Recruiting Phase 2 Mark Vincent Started 2021Primary completion 2026-06 NCT04335292

     osimertinib FDA EUpemetrexed

     Patients must have a known activating Epidermal Growth Factor Receptor (EGFR) mutation.

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-10-22Non-Small Cell Lung Cancer

334. Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

     Active, not recruiting Phase 2 Georgetown University Started 2021Primary completion 2026-11 NCT04958811

     tiragolumabatezolizumabbevacizumab

     Confirmed activating alteration in EGFR (cohort B only)

     Broad match: EGFR mutation (unspecified)Non-squamous Non-small-cell Lung Cancer

335. Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

     Recruiting Phase 1/2 Genprex Started 2021Primary completion 2028-03 NCT04486833

     quaratusugene ozeplasmidosimertinib FDA EUcisplatincarboplatin

     The NSCLC must be epidermal growth factor receptor (EGFR) mutation positive-positive based on results from most recent tissue biopsy or most recent evaluati…

     Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small Cell Lung

336. Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

     Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2021Primary completion 2027-12 NCT04940299

     ipilimumabnivolumabtocilizumab

     …CLC with EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).

     Broad match: EGFR exon 19 deletionClinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma, Locally Advanced Bladder Urothelial Carcinoma

337. Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

     Recruiting Phase 2 Fudan University Started 2021Primary completion 2026-12 NCT04136535

     pemetrexedcarboplatinanlotinib

     Presence of EGFR activating mutations and previously disease progression to Osimertinib (previously treated with 1st / 2nd gen…

     Broad match: EGFR sensitizing mutationNSCLC Stage IV

338. Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

     Active, not recruiting Phase 2 SWOG Cancer Research Network Started 2020Primary completion 2026-12 NCT04268550

     selpercatinib

     This includes EGFR sensitizing mutations, EGFR T790M, ALK gene fusion, ROS1 gene fusion, KRAS activating mutation, BRAF V600E mut…

     Broad match: EGFR sensitizing mutationRecurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

339. Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

     Recruiting Phase 2 Memorial Sloan Kettering Cancer Center Started 2020Primary completion 2027-05 NCT04410796

     osimertinib FDA EUcarboplatinpemetrexed

     Patients with detectable plasma EGFR mutations at C2D1

     Broad match: EGFR mutation (unspecified)Metastatic Non-small Cell Lung Cancer

340. PLATFORM Study of Precision Medicine for Rare Tumors

     Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020Primary completion 2026-07 NCT04423185

     aumolertinibdacomitinib FDA EUalectinibcrizotinibpyrotinibimatinibniraparibpalbociclibvemurafenibsintilimabatezolizumab

     when obtaining EGFR mutation, ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation, BRAF mutation, BRCA1/2 mu…

     Broad match: EGFR mutation (unspecified)Rare Tumor

341. A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

     Active, not recruiting Phase 2 AstraZeneca Started 2020Primary completion 2022-12 NCT04606771

     osimertinib FDA EUsavolitinib

     …Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

342. Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

     Active, not recruiting Phase 2 AstraZeneca Started 2019Primary completion 2024-08 NCT03778229

     osimertinib FDA EUsavolitinib

     …with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.

     Broad match: EGFR exon 19 deletionCarcinoma

343. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

     Active, not recruiting Phase 1/2 Dizal Pharmaceuticals Started 2019Primary completion 2024-07 NCT03974022

     sunvozertinib

     …ocumented histological or cytological confirmed locally advanced or metastatic NSCLC with EGFR or HER2 mutations.

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

344. Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

     Active, not recruiting Phase 1/2 AstraZeneca Started 2018Primary completion 2021-05 NCT03381274

     oleclumabosimertinib FDA EUAZD4635

     …sed with histologically or cytologically confirmed locally advanced/metastatic NSCLC with EGFRm

     Broad match: EGFR mutation (unspecified)Carcinoma, Non-Small-Cell Lung

345. Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

     Active, not recruiting Phase 2 University of Texas Southwestern Medical Center Started 2018Primary completion 2027-09 NCT03667820

     osimertinib FDA EU

     EGFR mutations may be demonstrated by standard, clinically accepted methods, including direct gene seque…

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer (NSCLC)

346. Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

     Recruiting Phase 2 National Cancer Institute (NCI) Started 2018Primary completion 2027-06 NCT03191149

     osimertinib FDA EU

     Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

     Broad match: EGFR mutation (unspecified)Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7

347. Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2016Primary completion 2023-02 NCT06303167

     osimertinib FDA EU

     …mertinib (AZD9291) in Patients With Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR

     Broad match: EGFR mutation (unspecified)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma

348. A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

     Active, not recruiting Phase 1/2 Takeda Started 2016Primary completion 2026-10 NCT02716116

     mobocertinib

     …one of the following documented by a local test: an activating mutation in EGFR including exon 19 deletions or exon 21 L858R substitution (with or without T790M), or an uncommon activating mutatio…

     Broad match: EGFR exon 19 deletionCarcinoma, Non-Small-Cell Lung

349. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

     Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2013Primary completion 2015-08 NCT01708954

     cabozantiniberlotinib FDA EU

     Tumor with a sensitizing mutation in epidermal growth factor receptor (EGFR), defined as follows:

     Broad match: EGFR mutation (unspecified)Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

350. Afatinib With CT and RT for EGFR-Mutant NSCLC

     Active, not recruiting Phase 2 Massachusetts General Hospital Started 2012Primary completion 2024-12 NCT01553942

     afatinib FDA EUcisplatinpemetrexed

     Have lung cancer harboring an EGFR mutation

     Broad match: EGFR mutation (unspecified)Lung Cancer

351. Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

     Active, not recruiting Phase 2 Massachusetts General Hospital Started 2009Primary completion 2015-05 NCT00977470

     erlotinib FDA EUhydroxychloroquine

     An EGFR sensitizing mutation must be detected in tumor tissue.

     Broad match: EGFR sensitizing mutationNon-small Cell Lung Cancer

352. CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

     Not yet recruiting Phase 1 Crimson Biopharm Starts 2027Primary completion 2029-07 NCT04933422

     CM93

     Archival tumor from initial or other prior surgery is documented to have EGFR mutation or EGFR amplification

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-08-21Glioblastoma

353. Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors

     Not yet recruiting Phase 1 Kangabio Started 2026Primary completion 2028-09 NCT07702955

     KGX105 injection

     Driver genes primarily include: EGFR exon 19 deletion, L858R mutation, or exon 20 insertion mutation.

     Broad match: EGFR exon 19 deletionAdvanced or Metastatic Solid Tumors

354. Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer

     Not yet recruiting Phase 1 Henan Cancer Hospital Started 2026Primary completion 2027-12 NCT07702305

     sacituzumab tirumotecan

     Pathologically diagnosed as EGFR mutation-positive non-small cell lung cancer;

     Broad match: EGFR mutation (unspecified)EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

355. An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

     Not yet recruiting Phase 1 Hansoh Pharma Started 2026Primary completion 2026-11 NCT07685041

     midazolam

     Confirmed EGFR mutation positivity in participants before enrollment.

     Broad match: EGFR mutation (unspecified)NSCLC

356. Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

     Recruiting Phase 1 Alpha Biopharma Started 2026Primary completion 2028-04 NCT07361705

     osimertinib FDA EU

     …riod, subjects must have a previous histological or cytological diagnosis of NSCLC with a sensitising EGFR mutation (including L858R and/or Exon19Del).

     Broad match: EGFR sensitizing mutationPatients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment

357. Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

     Recruiting Phase 1 City of Hope Medical Center Started 2026Primary completion 2031-11 NCT07544992

     Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells

     EGFR gene-altered by NGS or FISH analysis

     Broad match: EGFR mutation (unspecified)Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype

358. A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

     Recruiting Phase 1 EpiBiologics Started 2026Primary completion 2029-07 NCT07462377

     EPI-326

     o For NSCLC: the tumor harbors any documented EGFR mutation, insertion, or deletion.

     Broad match: EGFR mutation (unspecified)Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell

359. Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance

     Not yet recruiting Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026Primary completion 2028-10 NCT07842887

     All-trans retinoic acidtislelizumab

     …sensitizing EGFR mutation, including but not limited to an exon 19 deletion or an exon 21 L858R mutation.

     Broad match: EGFR L858REGFR-TKI-resistant Non-Small Cell Lung Cancer

360. A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

     Not yet recruiting Phase 1 Hansoh Pharma Started 2026Primary completion 2027-04 NCT07414953

     HS-10504SHR-A2009HS-20122HS-20117SHR-1826SHR-A2102

     Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；

     Broad match: EGFR mutation (unspecified)Lung Cancer

361. A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

     Recruiting Phase 1 Shanghai Junshi Bioscience Started 2025Primary completion 2028-04 NCT06839105

     paclitaxelcisplatincarboplatinpemetrexedoxaliplatincapecitabinebevacizumabRenvastinibAWT020

     Subjects with EGFR or ALK mutations will need to progress with prior treatment with appropriate kinase inhibitors.

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

362. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

     Recruiting Phase 1 Bayer Started 2025Primary completion 2027-08 NCT06804824

     VVD-159642sotorasibtrametinib

     any solid tumor that harbors an epidermal growth factor receptor (EGFR) alteration as per local/historical testing

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

363. A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations

     Recruiting Phase 1 Tongji University Started 2025Primary completion 2028-12 NCT07361237

     HJ-004-02 tablets

     Subjects must have non-squamous NSCLC with one or more positive EGFR mutations

     Broad match: EGFR mutation (unspecified)NSCLC (Advanced Non-small Cell Lung Cancer)

364. Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

     Recruiting Phase 1 Nuvectis Pharma Started 2025Primary completion 2026-12 NCT07315113

     NXP900osimertinib FDA EU

     Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.

     Broad match: EGFR mutation (unspecified)EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients

365. A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

     Recruiting Phase 1 Shanghai Institute Of Biological Products Started 2024Primary completion 2026-04 NCT06298058

     SIBP-A13 formulation for injection

     …cell lung cancer (NSCLC) confirmed by histology or cytology, with disease progression and EGFR mutation during or after treatment with third generation TKI and platinum containing therapy.

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

366. A Study of DM001 in Patients With Advanced Solid Tumors

     Active, not recruiting Phase 1 Xadcera Biopharmaceutical Started 2024Primary completion 2027-01 NCT06475937

     DM001

     …e pathologically or cytologically confirmed documented metastatic/advanced breast cancer, EGFRmut or EGFRwt NSCLC, gastric cancer, gastroesophageal cancer or CRC, and have progressed on s…

     Broad match: EGFR mutation (unspecified)Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Solid Carcinoma

367. A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

     Active, not recruiting Phase 1 Kumquat Biosciences Started 2024Primary completion 2026-12 NCT06507306

     KQB198osimertinib FDA EUamivantamab FDA EU

     … arms) and Part 2 Cohort A and Cohort B: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib

     Broad match: EGFR sensitizing mutationSolid Tumor, Adult

368. HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

     Not yet recruiting Phase 1 Newsoara Biopharma Started 2024Primary completion 2026-12 NCT06218940

     HY1272

     All patients must have documented EGFRm+, prior to enrolling in the combination therapy cohorts of this study.

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2024-01-23NSCLC Stage IV

369. A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

     Recruiting Phase 1 CSPC Started 2024Primary completion 2026-10 NCT07110883

     SYS6023

     …r (PR) ) expression for breast cancer participants, and Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) fusion, ROS Proto-Oncogene 1, receptor tyrosine kinase …

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumor

370. A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

     Recruiting Phase 1 Avistone Biotechnology Started 2024Primary completion 2028-02 NCT06046495

     PLB1004

     Have a documented EGFR mutation by a local test in tissue or plasma;

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer

371. A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

     Recruiting Phase 1 NextPoint Therapeutics Started 2024Primary completion 2027-08 NCT06240728

     NPX887

     …xpansion) and Part 1c (Randomized Dose Comparison): participants who have clear cell RCC, EGFR mutant lung adenocarcinoma, or gastric/GEJ adenocarcinoma.

     Broad match: EGFR mutation (unspecified)Metastatic Malignant Neoplasm

372. First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

     Recruiting Phase 1 Jubilant Therapeutics Started 2024Primary completion 2028-03 NCT07755397

     JBI-778

     EGFR-mutated non-small cell lung cancer (NSCLC) with or without brain metastases previously treated wi…

     Broad match: EGFR mutation (unspecified)NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck

373. A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

     Not yet recruiting Phase 1 Hansoh Pharma Started 2023Primary completion 2025-07 NCT05940116

     HS-20117

     …a study: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR-activating mutations who have progressed after or are intolerant to or not available to standard of care (SoC…

     Broad match: EGFR sensitizing mutationStatus may be outdated, last updated 2023-07-12Non-Small Cell Lung Cancer, Solid Tumor

374. Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

     Recruiting Phase 1 Karen Reckamp, MD, MS Started 2023Primary completion 2028-01 NCT05401110

     osimertinib FDA EUCarotuximab

     Stage IV or recurrent/metastatic non-squamous NSCLC that harbors an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q, etc).

     Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer, Lung Cancer

375. A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

     Recruiting Phase 1 Conjupro Biotherapeutics Started 2023Primary completion 2027-05 NCT05948865

     SYS6010

     In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) sugges…

     Broad match: EGFR mutation (unspecified)Cancer, Cancer, Lung

376. A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

     Enrolling by invitation Phase 1 Henlius Started 2023Primary completion 2026-12 NCT06115642

     HLX43serplulimab

     The standard treatment for non-squamous NSCLC with known EGFR mutations is defined as EGFR inhibitors and platinum-containing chemotherapy.

     Broad match: EGFR mutation (unspecified)Advanced/Metastatic Malignant Solid Tumors

377. Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

     Active, not recruiting Phase 1 ArriVent BioPharma Started 2022Primary completion 2025-06 NCT05364073

     furmonertinib

     … results from local testing of either tumor tissue or blood confirming the presence of an EGFR activating mutation, performed at a CLIA- or equivalently certified laboratory.

     Broad match: EGFR sensitizing mutationNon-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations

378. First in Human Study of AZD9592 in Solid Tumors

     Active, not recruiting Phase 1 AstraZeneca Started 2022Primary completion 2026-06 NCT05647122

     AZD9592osimertinib FDA EUfluorouracilleucovorinbevacizumab

     Histologically or cytologically confirmed metastatic or locally advanced EGFRmut., NSCLC

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

379. Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

     Active, not recruiting Phase 1 AbbVie Started 2022Primary completion 2027-11 NCT05599984

     ABBV-706cisplatinbudigalimabcarboplatin

     …euroendocrine carcinoma (LCNEC)s, SCLC transformed from epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), atypical lung carcinoids, and other high-grade poorly…

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumors

380. MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

     Recruiting Phase 1 Emory University Started 2021Primary completion 2026-12 NCT04762199

     Flt3/MerTK Inhibitor MRX-2843osimertinib FDA EU

     …nts must have histologically confirmed metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21

     Broad match: EGFR sensitizing mutationAdvanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8

381. A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

     Active, not recruiting Phase 1 HUYABIO International Started 2021Primary completion 2026-12 NCT05163028

     HBI-2376

     Advanced malignant solid tumors with KRAS or EGFR mutations diagnosed by histology or cytology

     Broad match: EGFR mutation (unspecified)Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor

382. A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

     Active, not recruiting Phase 1 Cullinan Therapeutics Started 2021Primary completion 2026-03 NCT05117476

     CLN-619pembrolizumabpaclitaxelcarboplatinpemetrexeddatopotamab deruxtecan FDA

     …1: Histologically or cytologically confirmed metastatic or locally advanced, unresectable EGFRm NSCLC.

     Broad match: EGFR mutation (unspecified)Advanced Solid Tumor, NSCLC

383. Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

     Active, not recruiting Phase 1 University of Utah Started 2020Primary completion 2024-01 NCT04141644

     ipilimumabosimertinib FDA EU

     Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

     Broad match: EGFR mutation (unspecified)Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

384. A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

     Active, not recruiting Phase 1 Ascentage Pharma Group Started 2019Primary completion 2025-12 NCT04001777

     APG-1252osimertinib FDA EU

     Cohort 3: Patients with advanced EGFR-mutated NSCLC not previously treated with TKI.

     Broad match: EGFR mutation (unspecified)EGFR Positive Non-small Cell Lung Cancer

385. WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

     Active, not recruiting Phase 1 Mayo Clinic Started 2019Primary completion 2022-10 NCT04197934

     WSD0922

     GBM/AA must either EGFR amplification and/or any activating EGFR mutation (e.g.

     Broad match: EGFR sensitizing mutationAnaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System

386. CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

     Active, not recruiting Phase 1 Jonsson Comprehensive Cancer Center Started 2019Primary completion 2026-01 NCT03546361

     Autologous Dendritic Cell-Adenovirus CCL21 Vaccinepembrolizumab

     Have received prior tyrosine kinase inhibitor therapy in patients with a sensitizing EGFR mutation and/or ALK gene rearrangement.

     Broad match: EGFR sensitizing mutationLung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

387. A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

     Active, not recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2018Primary completion 2027-06 NCT03567642

     osimertinib FDA EUPlatinumetoposide

     …dy of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

     Broad match: EGFR mutation (unspecified)Lung Cancer

388. AZD9291 in Combination With Ascending Doses of Novel Therapeutics

     Active, not recruiting Phase 1 AstraZeneca Started 2014Primary completion 2020-03 NCT02143466

     osimertinib FDA EUsavolitinibselumetinibdurvalumab

     …our harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including exon 19 deletion and L858R).

     Broad match: EGFR exon 19 deletionAdvanced Non Small Cell Lung Cancer

389. Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

     Enrolling by invitation Early Phase 1 Beijing Neurosurgical Institute Started 2025Primary completion 2027-12 NCT07520214

     mRNA vaccine: GV-907、GV-108

     …torial IDH-wildtype glioblastoma located in the frontal, temporal, or occipital lobe with EGFR gene mutation

     Broad match: EGFR mutation (unspecified)Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4

390. CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

     Not yet recruiting Early Phase 1 Second Affiliated Hospital of Nanchang University Started 2024Primary completion 2027-06 NCT06557096

     osimertinib FDA EUbevacizumab

     …tissue samples or blood samples are confirmed to have EGFR-sensitive mutations (including exon 19 deletions or L858R).

     Broad match: EGFR exon 19 deletionStatus may be outdated, last updated 2024-08-16Non Small Cell Lung Cancer, Circulating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer

391. A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

     Recruiting Early Phase 1 St. Joseph's Hospital and Medical Center, Phoenix Started 2023Primary completion 2027-12 NCT06072586

     silevertinibtemozolomide

     The tissue must have evidence of EGFR alterations including variants, fusion, and mutations with or without amplifications. rHGG participan…

     Broad match: EGFR mutation (unspecified)High Grade Glioma, Glioblastoma

392. ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase

     Recruiting No phase Shuanghu Yuan Started 2026Primary completion 2028-07 NCT07751536

     pemetrexed

     …g cancer (NSCLC) by cytology or histology, harbouring EGFR-sensitive mutations (including 19del and exon 21 L858R).

     Broad match: EGFR exon 19 deletionLeptomeningeal Metastasis From Lung Cancer

393. Dermatological Effects and Quality of Life in Oncology Patients

     Not yet recruiting No phase European Institute of Oncology Started 2026Primary completion 2027-10 NCT07869186

     Osimertinib: Adjuvant therapy in patients with common activating EGFR mutations for Non-Small Cell Lung Cancer (NSCLC) Amivantamab for advanced or metastatic EGFR-mutate…

     Broad match: EGFR sensitizing mutationBreast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer)

394. Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

     Not yet recruiting No phase Jiangsu Province Nanjing Brain Hospital Started 2025Primary completion 2025-10 NCT06766591

     ivonescimab

     EGFR mutation NSCLC

     Broad match: EGFR mutation (unspecified)NSCLC, Chemotherapy, Leptomeningeal Metastases, EGFR-TKI

395. Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

     Recruiting No phase Henan Cancer Hospital Started 2024Primary completion 2025-03 NCT06643000

     furmonertinibbevacizumabpemetrexed

     Genetic testing confirming positive for classical or non-classical EGFR mutations;

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation

396. A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC

     Not yet recruiting No phase Nir Peled Started 2023Primary completion 2027-12 NCT05698264

     Cohort A, confirmed EGFR mutation.

     Broad match: EGFR mutation (unspecified)Status may be outdated, last updated 2023-01-26Non Small Cell Lung Cancer, EGFR Gene Mutation, Immune Checkpoint Inhibitor

397. Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

     Recruiting No phase Instituto Nacional de Cancerologia de Mexico Started 2023Primary completion 2026-12 NCT06238882

     Nitroglycerin

     …ation Therapy vs Radiation Therapy Alone in Patients With Non-small Cell Lung Cancer With EGFR Mutations and Brain Metastases.

     Broad match: EGFR mutation (unspecified)Non-small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation

398. CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

     Recruiting No phase British Columbia Cancer Agency Started 2022Primary completion 2027-12 NCT05257967

     Histologically or cytologically confirmed metastatic EGFR mutant NSCLC.

     Broad match: EGFR mutation (unspecified)EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer

399. Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)

     Recruiting No phase Peking Union Medical College Hospital Started 2021Primary completion 2026-12 NCT05559645

     sunvozertinib

     in Cohort 5 with EGFR sensitizing mutation

     Broad match: EGFR sensitizing mutationNon Small Cell Lung Cancer